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introduction and aims of the study
Introduction
A. Platelets and Platelet-Rich Plasma (PRP).
Platelets are fragments of m egakaryocytes derived from the bone marrow. 
The diameter of a platelet is about 2 ^m. They have no nucleus and their 
live span is 7-10 days. Platelets contain three kinds of vesicles:
1. lysosomal vesicles with digestive enzymes.
2. dense vesicles containing adenosine diphosfate (ADP), which is a 
potent recruiter and activator of other platelets.
3. a-granules, containing several growth factors and fibronectin, 
which is a cell adhesive molecule. The growth factors proved to 
be present in these granules are: Platelet Derived Growth Factor 
(PDGF-AA, PDGF-BB, PDGF-AB), Transforming Growth Factor 
(TGF-|31, TGF-|32), Vascular Endothelial Growth Factor (VEGF), 
Epidermal Growth Factor (EGF). These growth factors are stored 
in an incomplete and, therefore, bio-inactive form.
W hen platelets become activated by the clotting process, a structural 
change of their cell membrane takes place and the a-granules migrate 
and fuse with the cell membrane. During this process, the biologically 
inactive growth factor proteins get a histone and carbohydrate side which 
makes them biologically active. Degranulation of the a-granules, begins 
w ithin 10 minutes of clot development and after one hour 90% of the 
prepackaged growth factors have been secreted34
Platelets are among the first cells to respond at a wound site and are critical 
to the initiation of wound healing because of the release of growth factors 27 
PDGF isomers (AA, BB, AB) have many corresponding properties and are 
the most universal growth factors in  wound healing. They act as mitogens 
for osteoblasts, endothelial cells, fibroblasts and mesenchymal stem cells
34. PDGF is a macrophage and neutrophil chemoattractant57. Macrophages 
elaborate multiple angiogenic factors 718. TGF-|3 is an indirect angiogenic 
factor and a macrophage chemoattractant. It also stimulates cell proliferation 
and the synthesis of collagen, fibronectin, elastin and proteoglycans 
27,32. VEGF plays an important role in the regulation of angiogenesis. It 
cooperates later with the angiopoietin system. After blood supply is 
adequate this process stops and may be regulated by oxygen tension 28. The 
effect of EGF is limited to the basal cells of skin and mucous membrane, 
inducing cell proliferation of these cells.
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Platelet-rich plasma (PRP) is an highly concentrated number of platelets 
in plasma. This may be an autogenous or homogenous product. Autogenous 
PRP, prepared by centrifuging in various cycles, always contains leucocytes 
from the buffy coat, because platelets cannot be completely separated from 
leucocytes by centrifuging. This means that there is also a substantial 
number of leucocytes in the PRP prepared. The blood bank reduces the 
remaining number of leucocytes to fewer than 1x106 by means of filtration. 
For patients with HLA antibodies, the blood bank prepares single donor 
platelets concentrates by means of cytaferesis. These, too, contain fewer 
than 1x106 per unit. Autogenous PRP can be prepared by blood bank 
procedures or by chair side appliances 5 45,69,70,75,76. One of the major 
advantages of the blood bank procedure is the optimal documentation of 
the product. Homogenous PRP, can only be m anufactured by the blood 
bank.
When PRP is activated by adding thrombin and calcium, it becomes gelatinized 
to a PRP gel. In the human setting, fibrin glue is used for this purpose. 
Fibrin glue is com posed of fibrinogen, factor XIII and some plasm a 
proteins, m ixed w ith throm bin and calcium . A lthough fibrin  glue can 
be prepared autogenously61, most of the tim e a commercially available 
product (Tissuecoll®) is used. After activating PRP, a high concentration 
of the above m entioned grow th factors is locally released. The basic 
hypothesis of adding PRP to bone grafts, is that high concentrations of 
these released growth factors, enhance the initial bone healing response. 
The direct in fluence of PRP w ill fade away soon and physiological 
m echanism s of bone repair w ill continue on an accelerated level21,47.
B. History of PRP
In 1970, the surgical use of fibrin glue was described by M atras35. Interest in 
fibrinogen as a surgical adhesive or sealant began in the early 1990's. Since 
then experience w ith fibrin glue has been extensive in Europe and Japan, 
especially in thoracic and cardiovascular surgery to improve hemostasis 
and, therefore, reducing the need for blood transfusion. Because of fear of 
potentially transm itting hepatitis or other viruses, such as HIV, from the 
homologous pooled plasma source, it was not commercially available in 
the USA. To obviate this problem, the use of autogenous platelet gel (APG) 
from intraoperatively collected autogenous PRP had been introduced by 
Oz MC et al.46 in 1992 and in a modified fashion by Tawes et al.62 in 1994. 
The critical difference in composition betw een platelet gel and fibrin
16
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glue is the presence of a high concentration of platelets and a native 
concentration of fibrinogen in platelet gel. The presence of platelets in 
platelet gel brings growth factors and cytokines to the site of surgery in a 
m anner that would not occur w ith fibrin glue. Therefore, these autogenous 
platelet gels would not only improve hemostasis, but also might have 
benefits which include an acceleration in bone and wound healing and a 
reduction of postoperative infection and postoperative pain71.
In oral and m axillofacial surgery, homologous fibrin glue was introduced 
by M atras36 in 1982, who presented some case reports on the use of fibrin 
glue in soft tissue hemostasis, split skin graft procedures, communitive 
fractures and the closure of the lam ina dura.
In 1994 Tayaponsak et al.63, described the use of autogenous fibrin adhesive 
in mandibular reconstruction with particulate bone grafts. In addition to 
the adhesive and haemostatic properties of this autogenous fibrin adhesive, 
they demonstrated radiographically that the remodelling process began 
about two times earlier as compared to the control group in a series of 33 
cases. It was thought that the fibrin adhesive provided the substratum 
for migration of m esenchymal cells, accelerating revascularization and 
migration of fibroblasts, stim ulating the growth of both fibroblasts and 
osteoblasts. W hitm an et al.71 (1997) reported on the use of autogenous 
platelet gel in various applications in oral and m axillofacial surgery 
to enhance wound healing. Platelet gel was formed by m ixing PRP, 
derived from differential centrifugation of autogenous whole blood, with 
throm bin and calcium. In 1998, Marx et al.32 reported on a study of 44 
cases of secondary m andibular reconstructions using autogenous PRP 
(with a 4 to 5 fold increase over baseline platelet numbers) added to the 
particulate cancellous bone graft. Radiographic m aturation was increased 
to a rate of 2.16, 1.88 and 1.62 tim es com pared to grafts w ithout PRP 
(44 cases) at 2, 4 and 6 months respectively. Also at six month, bone 
grafts with PRP demonstrated greater trabecular bone density than did 
bone grafts without PRP.
After Marx et al.32 presented these remarkable positive results on the 
use of PRP, the easy availability of autogenous PRP has prompted a 
magnitude of clinical applications, which however, were rarely based on 
a controlled design, but mostly reported as clinical observations without 
a well-defined set of success parameters or a control group56.
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Several in vivo anim al and hum an and in vitro studies have also 
been performed, revealing rather contradictory results, but never with 
comparable positive effects as presented by Marx et al.32.
C. Platelet-rich plasma in animal experimental and in vitro studies
Several anim al studies have reported a significant beneficial effect of PRP 
on bone healing. Some of them concern bone formation around implants 
in the iliac crest of dogs26, the frontal skull of pigs54 and the mandible of 
m inipigs74, while Fennis et al.12 reported on bone formation and vascular 
ingrow th in unilateral defects of the mandible in  goats. In contrast, other 
anim al studies revealed no beneficial effect of PRP on bone healing in 
non-critical size defects in the cranial bone of rabbits1,49 and in critical size 
defects in the forehead of pigs55,72,65. Choi et al.9 even described an adverse 
effect of the addition of PRP to bone grafts, in  that bone formation was 
reduced w ith the addition of PRP, using bilateral continuity defects of the 
m andible in dogs.
Several factors may play a role in  these conflicting results.
1. The variation in tim e intervals at which the measurements were 
carried out. Because the life span of a platelet in a wound and the 
direct influence of its growth factors is less than 5 days33 a pronounced 
effect of PRP would be expected to occur especially in the (very) early 
stage of wound healing. In the anim al experim ental studies mentioned, 
the time intervals that were chosen differed and most of them were 
not related to (very) early wound healing: Aghaloo et al.1: 1,2 and 4 
month, Kim et al.26: 6 and 12 weeks, Zechner et al.74: 3, 6 and 12 weeks, 
Schlegel et al.54: 2, 4 and 8 weeks, Choi et al.9: 6 weeks, Fennis et al.12: 
3, 6 and 12 weeks, W iltfang et al.72: 2,4 and 6 weeks, Schegel et al.55: 
2,4 and 12 weeks, Thorw arth et al.65: 2,4,12 and 26 weeks, Plachokova 
et al.49: 1 and 2 weeks.
2. The different anim al species and the operation sites used in the several 
experim ental anim al studies make it difficult to compare the results 
of these studies.
3. The variation in the concentration of platelets in  the PRP used, 
however, may be a major reason to explain the less than consistent 
results. This may be due to the great variation in the baseline value 
of the concentration of platelets in different kinds of animals 37. W hen 
instead of the individual value, the average value of platelets in the 
peripheral blood of a anim al species has been taken as a starting
18
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point for the baseline value, without taking into account the great 
variation mentioned, results can easily be misleading. There is also 
often a lack of inform ation about the blood products used. In several 
studies, no inform ation has been given about the baseline value of
platelets in the peripheral blood of the anim als used12,26,39,49,54,55,74. In 
some studies the concentration of the platelets in the PRP used was 
not even mentioned at all26,54,55. Some authors rely on the results of 
other studies using desktop devices (Curasan® and 3i®) and supposed 
that in their experiment the same results were obtained using these 
devices55. Choi et al. 20049, however, demonstrated in a dog model, that 
the multiplication of the individual baseline of platelets in PRP varied 
(range 4.5-8.5 times the baseline value) using the same preparation 
technique. The level of the multiplication was also independent of the 
individual baseline value of the platelets.
Apart from the differences in the PRP's used, it can also not be ruled out 
that there is a discrepancy in the concentration of platelets needed for 
acceleration of bone formation in different anim al species.
In vitro studies, in which very early effects of PRP can be measured, 
revealed beneficial effects of PRP. From the thirty-eight in vitro studies 
performed over the last eight years, 81.5% reported significantly positive 
effects of PRP on the proliferation rate of different types of cells, mostly 
osteoblast(-like) cells and mesenchymal stem cells2,3,4,6,8,10,11,13,16,17,19,20,22' 
25,29,3o,31,4o-44,48,52,6o,66,67,68,7:3. Seven (18.4%) of these studies reported a significant 
increase of the proliferation rate when PRP was used at a relatively low 
concentration (platelet concentration range 12x109/l - 280x109/l). Higher 
PRP concentrations generally caused a decrease in cell proliferation10,16,19, 
29,30,48,68. In one study, using eight different concentrations of hum an PRP 
(range 0.38-2.86 times the baseline value) no significant positive effect 
on the proliferation rate was observed59. No conclusions could be drawn 
about the differentiation of different types of cells used in several studies. 
Differentiation was stimulated significantly in 8 (21.1%) 4,17,23,24,25,30,66,67 and 
decreased significantly in 6 (15.8%) studies 6,40,43,44,60,73 Unfortunately, the in 
vitro studies mentioned used different experim ental set-ups (i.e. variation 
in cell origin, seeding density, temporal sampling, PRP preparation 
procedures, platelet concentrations used, etc.).
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D. Platelet-rich plasma in human skeletal reconstruction.
The m ajority of hum an studies using PRP in skeletal reconstructions, 
have been done by oral and m axillofacial surgeons. Several reviews on 
the use of PRP have been published14,15,53,56, but only Plachakova et al.50
presented the first systematic review, including its application in dentistry 
and oral and m axillofacial (OMF) surgery. The authors concluded that 
overall, the m ajority of the reviewed studies reported a positive effect 
of PRP on bone regeneration. The quality assessment of these studies, 
judged by their reports, however, revealed that most of them did not meet 
current recommendations on study design and for that reason cannot 
be used as evidence. A substantial heterogeneity was observed in this 
review. The authors suggested that the difference in protocols, as used for 
PRP production, may be one of the reasons. They stress the importance 
of a detailed description of the protocol for PRP production. Based on 
the results of the selected studies (9 out of 108), they found evidence for 
beneficial effects of PRP in the treatment of periodontal defects. Evidence 
for beneficial effects of PRP in sinus elevation appeared to be weak and no 
conclusions could be drawn about other applications of PRP in dentistry 
and OMF surgery.
Reconstruction in mandibular continuity defects, however, also may be 
an indication using PRP. Pogrel et al.51 concluded that the failure rate of 
non vascularized bone grafts, in  which no PRP was used, was 17% when 
the defect was 6 cm or shorter, increasing to 75% for grafts over 12 cm 
in length. At present, there are four studies; Marx et al.32, Merkx et al.38, 
Thorn et al.64, and Simon et al.58 that report good results in mandibular 
reconstruction dealing w ith relatively large mandibular defects. Their 
results compare well with the results as reported by Porgel et al.51. 
Although it should be realised that these studies on hum an beings are, 
for comprehensible reasons, not prospectively randomized and have no 
control sites, whilst consisting of a heterogeneous group of patients.
Considering all current data, the scientific evidence for the additional 
value of PRP in skeletal reconstruction is still debatable. At the beginning 
of the current project, however, PRP seemed to be a very promising 
product. PRP seemed to enable the surgeon to undertake reconstructions 
with non-vascularized bone grafts that were hitherto impossible.
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The first hypothesis is that adding PRP, with high concentrations of the 
released growth factors, to bone grafts, enhance the initial bone healing. 
Because the life span of a platelet in a wound and the early influence of 
its growth factors is less than 5 days33, a pronounced effect of PRP should 
be expected, especially in the early stage of bone healing.
The second hypothesis is that there is a direct relation betw een the 
number of platelets and the levels of their growth factors, which may 
have influence on the effect of PRP on osteoblasts and angiogenesis . 
Consequently, the aims of the present study were as follows:
1. To investigate the early and late effects of PRP on bone healing.
2. To investigate the early and late effects of PRP on bone healing of a 
m ixture of autogenous bone and a bone substitute
3. To quantify the growth factors of PRP in 3 different species and to 
study the effect on rat bone marrow cells.
4. To quantify the concentration of several growth factors w ithin two 
different concentrations of hum an PRP.
5. To study the effect of these different concentrations of PRP on rat 
osteoblast-like cells.
6. To define the optimal concentration of PRP to stimulate early 
angiogenesis.
7. To evaluate the effect of PRP for the reconstruction in large mandibular 
defects in hum an beings
21
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the effect of platelet-rich plasma on early and late bone healing: a study in goats
Introduction
Platelet-rich plasma (PRP) is currently widely used in experim ental as 
well as reconstructive surgery to improve bone healing6, 8 9 13, 20, 21, 24, 27. There 
are, however, conflicting data in the literature about its effectiveness, that 
require further research.
Several anim al studies have shown a significant beneficial effect of PRP 
on bone healing. Some of them concern bone formation around implants 
in the iliac crest of dogs9, the frontal skull of pigs21 and in the mandible of 
m inipigs27, while Fennis et al.5 reported on bone formation and vascular 
ingrowth in unilateral defects of the mandible in goats. In contrast, other 
anim al studies revealed no beneficial effect of PRP on bone healing in 
non-critical size defects in the cranial bone of rabbits1 and in critical size 
defects in the forehead of pigs22, 25. Schlegel et al.22 and Wiltfang et al.25, 
initially (within 2 weeks) found a positive effect of a relatively high 
concentration of PRP on m ineralization, when autogenous bone was used. 
After 12 weeks, however, the rate of m ineralization was sim ilar in the 
different experim ental sites, w ith or without the use of PRP. Choi et al.3 
describe even an adverse effect of the addition of PRP to bone grafts in 
that bone formation was reduced with the addition of PRP, using bilateral 
continuity defects of the mandible in dogs.
The use of PRP is based on the assumption, that a 4 or 5 times concentration 
of autogenous platelets releases significant quantities of growth factors, 
that aid b one healing15. Because the life span of a platelet in a wound and the 
direct influence of its growth factors is less than five days14, a pronounced 
effect of PRP would be expected to occur especially in the early stage of 
bone healing. There is, however, an apparent lack of inform ation on that 
early effect of PRP on bone healing. In anim al experiments, studying the 
histological effects of PRP on bone healing, the tim e intervals that were 
chosen differed. By Aghalo et al.1 and Kim et al.9 tim e intervals of four 
weeks and longer were chosen. Zechner et al.27 studied the experimental 
sites at tim e intervals three, four and twelve weeks. Time intervals of 
two, four and eight weeks where chosen by Schlegel et al.21. In these 
experiments, however, the effect of PRP on bone healing was studied in 
non-critical size defects in rabbits1 or around dental implants in dogs and
(mini) pigs 9, 21, 27.
33
chapter 2
Considering the short life span of platelets, it was hypothesized that 
PRP would have an early effect on the healing of bone. This is important 
to know, because early visible effects would imply acceleration of bone 
healing. This could have clinical significance, especially in cases were 
radiotherapy is needed.
In our study a goat model was selected as previous studies, in the same 
institution, showed that a round defect in the forehead of a goat, with a 
diameter of 14 mm, is critical; at least at twelve weeks post operatively18. 
Bone healing in these critical size defects, using particulate autogenous 
cancellous bone grafts, was completed betw een six and 12 weeks post 
operatively.
Material and methods
Surgery
Previous studies already confirmed that critical size defects in a goat model 
cause negligible discomfort for the anim als18. This caused the Anim al 
Ethical Committee of the University of Nijmegen to grant perm ission for 
further studies using this model.
Twenty female Saanen goats, weighing about 65 kg, were used. Before 
surgery, a blood sample of the goat was taken to ensure that the animal 
was CAE/CL arthritis free. The anim als were housed in a stable. National 
guidelines for the care and use of laboratory animals were obeyed.
The operation was performed under general anaesthesia. The anaesthesia 
was induced by an intravenous injection of pentobarbital and m aintained 
by isoflurane 2-3% through a constant volume ventilator, administrated 
through an endotrachael tube. The goat was connected to a heart monitor.
To reduce the risk of peri-operative infection, the goat was treated with 
three gifts of ampicilline, the second and third gift were depots.
- during the operation : Albipen® 15%, 3 ml/50 kg s.c.
- day one post-op : Albipen® L.A. 7.5 m l 15%, 3 ml/50 kg s.c.
- day three post-op : Albipen® L.A. 7.5 m l 15%, 3 ml/50 kg s.c.
Before surgery, the skin at the operation sites was shaved and disinfected 
using povidine iodine-solution. To harvest cancellous bone from the an­
terior iliac crest, an incision with a length of five cm was made on top
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of the iliac crest, subse­
quently subperiosteal el­
evation was carried out 
on the lateral aspect of 
the crest. About five bi- 
cortical bone plugs were 
harvested by means of a 
trepan18.The wound was 
closed in layers using 
resorbable sutures (Vic­
ryl®, Ethicon, Johnson &
Johnson).
Considering a particulate 
cortical bone graft does 
not heal in a predict­
able fashion in the same 
goat model19, the cortical 
bone was split from the 
cancellous bone using an 
osteotome and was not 
used in this experiment.
This cancellous bone was 
ground in a bone-m ill 
(Leibinger®, Freiburg, Fig. 1 The four experimental sites (defects) A and C 
Germany) and four por- filled with 0,6 gr cancellous bone B and D filled with 
tion s of each 0.6 gr were 0.6 gr cancellous bone and 1ml PRP each 
prepared.
A longitudinal mid-sagittal incision was made over the forehead of the 
goats and subperiosteal elevation was carried out bilaterally. Four full 
thickness critical bone defects18 were made with a hollow cylindrical 
trepan (standard outer diameter 14 mm) in the frontal bone overlying the 
frontal sinus, leaving the mucosal lining and its fibrous attachment to the 
inner table around the defect intact.
W hilst removing this round full thickness frontal bone fragments, in 
approximately 50% of the cases, bony septae becam e visible beneath the 
removed bone. In these cases the mucosa was carefully stripped from 
these septae, after which they were reduced with a roncheur. The mucosa 
was than closed using 5-0 Vicryl® sutures.
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Dental pins (Stabilok®, Wimbledon Village, London) were inserted in the 
bone adjacent to each defect to facilitate orientation. One dental pin at 
defect A and at defect C versus two dental pins at defect B and D each. 
Defects A and C were subsequently filled with 0.6 gram of cancellous bone. 
The other two defects (D and B) were filled with 0.6 gram cancellous bone 
mixed with 1 m l PRP (Fig. 1). Platelets are highly (but reversible) activated 
shortly after collection of whole blood and show spontaneous aggregation. 
These aggregates disappear, however, after a resting period of 16-20 
hours at room temperature. These platelets have equal in vitro quality 
compared to platelets that were produced from whole blood that had been 
stored for 6 hours. For logistic and uniform  processing of whole blood, 
cooling the units to room temperature w ithin two hours and a subsequent 
storage period of about 16-20 hours until separation into components is 
preferred16. For this reason, 250 cc of autogenous blood was drawn one day 
before surgery. This blood was treated by centrifugation at the transfusion 
laboratory in various cycles4. In this way, a platelet-rich plasma suspension 
was obtained (platelet count exceeding 800x109/l). Because the mean 
platelet count in whole blood of goats is 171 (±19,6)x109/l 4, a 4 to 5 fold 
increase over baseline platelet numbers was achieved. This was activated 
at the time of surgery with 1 cc 10% calcium chloride solution and 300 I.U. 
of bovine thrombin (Fibriquick® Organon Teknica, Durham, US) to form a 
gel 20, 23, whilst the erythrocytes were given back10, 13.
Histological preparation
All animals were sacrificed by an overdose of pentobarbital as shown below.
Group 1 (N=5) after 1 week
Group 2 (N=5) after 2 weeks
Group 3 (N=5) after 6 weeks
Group 4 (N=5) after 12 week
The frontal bone of each goat was resected and stripped of the soft tissue 
leaving a thin layer of connective tissue over the experim ental sites. 
These specimens were stored in a 4% phosphate-buffered formaldehyde 
solution (pH=7.4) for fixation. After fixation, the frontal bone was 
divided in four parts, each containing one experim ental site. These 
parts were then dehydrated in graded series of alcohol and embedded in 
methylmethacrylate. After polymerisation, each part was divided in such 
a way that the experim ental site was split into two halves. One half was 
used to make three 10 ^m  transverse sections using a modified microtome
36
the effect of platelet-rich plasma on early and late bone healing: a study in goats
technique12. The sections were etched with hydrochloric ethanol and 
subsequently stained with methylene blue and basic fuchsin. Light- 
m icroscopical analysis consisted of a description of the tissue response 
w ithin the grafted area.
Histomorphometry
Each experimental site was 
quantitatively assessed 
using a grading scale for 
bone formation (at the two 
edges of the defect) and 
for bridging of the defect 
(Table I).
In all groups,
histomorphometry was 
performed on the sec­
tions to quantify the bone 
fill percentage of newly 
formed bone and grafted 
bone in  a plane perpen­
dicular to the grafted 
area, called 'the surface of the defect' and in the area of interest i.e. area 
between the edges of the defect. For this purpose a Leica Qw in Image 
Processing and Analysis System (Cambridge, UK) was used. The sections 
were digitized at low magnification.
In each slide the outline of the surface of the defect and of the region of 
interest was marked by one investigator (Fig. 2a). The newly formed bone 
as well as the grafted bone was marked in an interactive m anner (Fig. 2b). 
The computer calculated the area of the surface of the defect, the area 
of the region of interest and the bone surface (newly formed bone and 
grafted bone). From these data the bone fill percentage in the surface of 
the defect and in the region of interest was calculated dividing the bone 
surface area by the area of the surface of the defect and by the area of the 
region of interest respectively.
Table 1. Scoring system of bone formation at the edges 
and bridging of the defect.
Categories Scores
Bone formation at the edges of the defect
None 0
One edge 1
Two edges 2
Bridging of the defect (%)
0-25 0
25-50 1
50-75 2
75-100 3
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Fig. 2 (a) Histological slide stained with methylene blue and basic fuchsin. 
The continuous (black) line contains the region of interest (ROI) and the 
dotted (white) line contains the surface of the defect. (b) Newly formed bone 
and grafted bone (both green) in the surface o f the defect and in the region of 
interest.
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Statistical analysis
The results were statistically evaluated, the semi-quantitative m easure­
ments by means of the Pearson Chi-Square test and the results of the 
histomorphometry by means of the ANOVA test. Differences were consid­
ered statistically significant if p<0.05. All charts show error bars depicting 
the standard deviation.
Results
Recovery and healing were uneventful in  all goats without any signs of 
infection or wound dehiscences.
Descriptive histology
Light-microscopic exam ination of the sections of the sacrificed goats 
revealed no differences betw een the PRP and the non- PRP group.
At one week, there was a lim ited inflammatory response. There were no 
signs of resorption of bone neither at the edges of the defect nor at the 
grafted particles. No empty lacunae in the grafted bone particles, caused 
by absence of osteocytes, were observed. No osteogenic activity at the 
edges or at the surface of the grafted particles was seen. There was only a 
small amount of fibrous tissue in the grafted area.
At two weeks, a lot of inflammatory cells, lymphocytes and giant-cells were 
seen. There were moderate signs of resorption of the grafted particles, 
showing irregularities and osteoclast-like cells. Some empty lacunae in 
the grafted bone particles were also observed. New bone formation was 
found m ainly at the bony edges of the defect, but no osteocytes were seen. 
There was a lot of fibrous tissue betw een the grafted bone particles.
At six weeks, there were no signs of inflammation. Only a few originally 
grafted bone particles could be detected. Compared to week one and 
week two post-operatively, the number of grafted bone particles had 
substantially decreased. Some empty lacunae were seen in the grafted 
bone particles. On the other hand bone formation in the whole grafted area 
was observed and only a small amount of fibrous tissue was present.
At twelve weeks, there were no signs of inflam m ation either. Some grafted 
bone particles were observed, but they were difficult to differentiate 
from the surrounding bone. This was also true for the edges of the initial
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defect. The sections showed only a few empty lacunae. Bone formation 
with inclusion of osteocytes could be seen in the whole grafted area and 
there was very little fibrous tissue left w ithin this area.
Histomorphometry
No statistically significant differences were found betw een the sites with 
and without PRP. This held true for bone formation at the edges of the 
defect (Table 2) as well as the bone bridging the defect (Table 3). In all 
cases p was (>>) > 0.05 (Pearson Chi-Square test).
Table 2. Bone formation at the edges of the defect
Weeks
Bone formation
Sites examinedNone One edge Two edges
1 PRP 10 10
Non-PRP 10 10
2 PRP 3 4 3 10
Non-PRP 3 5 2 10
6 PRP 0 1 9 10
Non-PRP 1 0 9 10
12 PRP 0 10 10
Non-PRP 1 9 10
Table 3. Degree of bridging of the defect
Bridging
Weeks 0 - 25 % 2 5 - 5 0 % 5 0 - 75 %  75 - 100% Sites examined
1 PRP 9 1 0 0 10
Non-PRP 10 0 0 0 10
2 PRP 5 3 2 0 10
Non-PRP 7 3 0 0 10
6 PRP 1 1 1 7 10
Non-PRP 3 1 0 6 10
12 PRP 0 0 1 9 10
Non-PRP 0 1 0 9 10
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—Control
-P R P
Fig. 3. Surface of the defect.
Fig. 4. Bone fill percentage 
in the defect and in the 
region of interest (ROI).
T im e  [weeks]
♦ ROI, Control 
—B - R O I ,  P R P  
—A — Defect, Control 
- X -  Defect, P R P
One week post-operatively, no bone formation was seen at all at the edges 
of the defect, neither was bridging present in 19 out of 20 sites.
At two weeks, in nine sites bone formation was seen at one edge and in 
five sites at two edges. Bridging was seen at a m aximum of 50-75% of the 
distance of the two edges in two cases. In both cases PRP was used.
At six weeks, 18 (out of 20) and at twelve weeks 19 (out of 20) sites showed 
bone formation at two edges. At six weeks 75-100% bridging was seen in
13 out of 20 cases, at twelve weeks this was the case in 18 out of 20 cases 
(Table 2 + 3).
Concerning the surface of the defect, the bone fill percentage of the defect 
and the bone fill percentage of the region of interest, no statistically 
significant differences were found between the sites with and without 
PRP, All p-values were >> 0.05. (ANOVA test)
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The surface of the defect decreased in time (Fig. 3). A statistically significant 
difference was found between group one and two and group three and 
four. No statistically significant difference was found, however, between 
group three (six weeks) and group four (twelve weeks).
The bone fill percentage of the defect increased in  tim e (Fig. 4). A statistically 
significant difference was found between group one and two and group 
three and group four. No statistically significant difference, however, was 
found betw een group three and group four and neither betw een group 
one and group two.
The bone fill percentage in the region of interest first decreased and 
than increased in tim e (Fig. 4). A statistically significant difference was 
found betw een group one and two and group three and group four. 
No statistically significant difference was found betw een group three and 
group four neither betw een group one and group two.
Discussion
The hypothesis of this study, that the addition of PRP to a bone graft in 
a critical size defect of the frontal bone of a goat, has a positive effect on 
early bone formation, had to be rejected.
The results of the histologic and histomorphometric exam inations showed 
that the early and late bone healing was not enhanced when PRP was 
used.
There are several reasons to explain these results. W hen carrying out this 
study, we relied on the data as reported by Clemmons et al.4, i.e. that the 
normal platelet count in goats is 171 (±19.6)x109/l. Unfortunately, at the 
time this study was carried out, it was not possible to define the baseline 
values of each animal. This was due to the fact that, in  goats, red blood 
cells are very small and, therefore, almost indistinguishable from platelets 
when counting by an analyst, using a microscope. According to M arx15, 
in hum an beings, a sufficient cellular response to platelet concentrations 
first begins when a 4 to 5 fold increase over baseline platelet numbers is 
achieved. The in this study achieved concentration of ± 800x109/l would 
imply a 4 to 5 times concentration compared with the baseline value. 
There are, however, other reports indicating a much higher baseline 
concentration of platelets in goats; Breukink et al.2 3 08-628x109/l, Lewis11 
551(±92)x109/l, Merck m anual17 300-600x109/l. It is, therefore, likely that
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the concentration of platelets, as used in this experiment, was only 1.3 to 
3 times the baseline concentration. Fennis et al.5, nevertheless, found a 
significant beneficial effect of PRP (platelets >800x109/l) on bone healing 
(bone fill percentage) and angiogenesis (vascular in growth) six and 
twelve weeks postoperatively. At three weeks, however, no relevant effect 
of PRP was seen. Therefore, a platelet concentration exceeding 800x109/l 
proved to be statistically beneficial in bone healing using a goat model, at 
least at tim e intervals of six and twelve weeks5. In the present study, the 
same procedure to make PRP was used. The surgical site, however, was 
different. Fennis et al.5 made a unilateral continuity defect in the mandible 
of goats w ith a fairly sizable bone stump on each side. In the present study, 
the height of the bone, surrounding the circular defect, varied from only 1 
to 2 mm. The border of the posterior part of the defect in the present study 
consists of respiratory epithelium, which is not osteoinductive and may 
act as a resorptive endosteum28. Fennis et al.5 used a particulate cortico- 
cancellous bone graft, whilst in the present study only a particulate 
cancellous bone graft was used, because particulate cortical bone grafts 
proved not to heal in a predictable fashion19. It remains, however, unclear 
whether these differences explain why beneficial effects of PRP could not 
be observed in the present study.
The only similar study, using the same goat model but without using PRP, 
was carried out by Merkx et al.19. Several histological differences between 
the results presented and those of Merkx et al.19 were seen. Merkx et al.19 
found most of the lacunae in the grafted particles were empty at three 
weeks postoperatively, whereas in  the present study only some empty 
lacunae were seen at two weeks postoperatively. At six weeks, a small 
amount of fibrous tissue and some empty lacunae were seen, which was 
in contrast w ith the findings of Merkx et al.19 at that time interval. Twelve 
weeks postoperatively, some grafted particles were observed and they 
were difficult to differentiate from the surrounding new bone. This was 
also in contrast with the findings of Merkx et al.19, who described a defect 
that was totally filled with bone chips embedded in new bone, but still 
recognizable.
Looking at the different observations betw een the study of Merkx et al.19 
and the present study, PRP may have played a role. Since empty lacunae 
are indicative for non-vital bone, it seems that in the present study more 
vital grafted bone particles were seen as compared to the study of Merkx 
et al.19. This is in keeping with the findings of Fennis et al.5, who also 
described that in the non-PRP group, more of the grafted bone was seen
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to be non-vital. In contrast w ith the observations of Merkx et al.19 a lot of 
resorption of the grafted bone particles took place betw een two and six 
weeks postoperatively. Fennis et al.5 observed m inim al signs of resorption 
of the grafted bone particles and hardly any osteoclast like cells at three 
weeks postoperatively, whereas at six weeks resorption of the grafted 
bone particles was seen more often in the PRP group.
In the present study the Quantitative analysis revealed no significant 
differences between the experim ental and the control sites at all time 
intervals. In time, some changes took place in the experim ental as well 
as in the control sites. The surface of the defect, reflecting its shape, 
changed significantly betw een two and six weeks postoperatively. W ithin 
this period, the shape of the defect decreased until, at six weeks, the 
pre-operative shape of the frontal bone had almost been achieved. The 
above mentioned period concurs with the period in which a substantial 
resorption of the grafted bone particles and dim inishing of the fibrous 
tissue took place. The bone fill percentage of the defect and the bone 
fill percentage of the region of interest, on the other hand, increased 
significantly between two and six weeks. This could, however, be 
caused by dim inishing and contraction of the fibrous tissue inside the 
defect, because at six weeks only a small amount of fibrous tissue was 
seen. Because Merkx et al.19 did no quantitative histological analysis, the 
above mentioned quantitative findings of the present study could not be 
compared w ith their study.
Another reason to explain why no effect of the use of PRP could be 
observed, may be that the early vascular ingrow th and early osteoid 
deposition is not detectable by using only methylene blue and basic 
fuchsin as has been the case in the present study. Goldener's Masson 
trichrome staining would have allowed for good cellular staining due 
to the haem atoxylin component with concomitant sharp discrim ination 
of mature bone m atrix and im mature new bone in plastic embedded 
undecalcified bone specimens7. It may also be possible that diffusion of 
PRP and/or its growth factors from the experim ental to the control sites 
underneath the periosteum on the outer site of the frontal bone, took 
place. If this had been the case, it could have affected the results between 
the experim ental and the control sites.
The results presented increase the existing confusion, due to conflicting 
results as reported in  various experim ental studies using PRP in animals. 
There are probably two major reasons; the average concentrations used
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in the various studies did not take into account the great variation in  the 
baseline values of the anim als17 and the variation in the concentration 
of platelets in the PRP used1. In some studies the concentration of the 
platelets in PRP was not mentioned at all9, 21. It is, therefore, probably 
better to use absolute values of platelet concentrations in  PRP that would 
provide enough growth factors to stimulate bone formation. It can also not 
be ruled out that there is a discrepancy in the concentration of platelets 
needed for acceleration of bone formation between different sorts of 
animals. This would imply that the results of anim al studies can not be 
directly translated to hum an beings without taking this into account. 
Consequently, it has to be recommended that the critical effective amount 
of platelets in  each sort of anim al should be defined by experim ental 
studies. There is also an obvious need for standardizing the concentration 
of platelets in PRP, if studies are to be compared.
In conclusion, anim al studies reporting on the effects of PRP, including 
the present study, should be interpreted with the above mentioned 
considerations. Before continuing performing experiments, studying the 
effect of PRP on bone healing, it seems to be important to standardize the 
preparation of PRP. There are two possibleroutes to achieve standardization. 
1e An absolute value of the concentration of thrombocytes, based 
on a 4 to 5-fold increase over the mean baseline platelet numbers, 
independent of the individual baseline platelets numbers of each animal. 
2e A value of the concentration of thrombocytes, based on a 4 to 5-fold 
increase over the individual baseline platelets numbers of each animal. 
It remains to be explored which of the two would be the most effective.
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Introduction
There is a continuing search for bone substitutes to avoid or m inim ize the 
need for autogenous bone grafts. For example, an often observed problem 
is that an appropriate amount of autogenous bone needed for complete 
filling of a bone defect cannot be harvested. To solve this problem, the 
harvested autogenous bone can be m ixed with an alloplastic or synthetic 
bone graft in  order to increase the volume of the graft. Of course, the graft 
has to support bone healing. One of the frequently used allogenic grafts 
consists of deproteinized bovine bone m ineral (Bio-Oss®). This material 
contains pores of different sizes, i.e. macro pores (300-1500|jm), micro 
pores (Haversian and vascular marrow canals) and intracrystalline spaces 
(3-26nm), which results in a high overall porosity of 70% to 75% 10,24. As a 
consequence of this highly porous structure, Bio-Oss® can easily be invaded 
by blood vessels resulting in subsequent m igration of osteoblasts6,12. 
In view of this, Bio-Oss® is considered to be an osteoconductive and 
biocompatible m aterial evoking no significant inflammatory reaction 6 8,38. 
For example, Jensen et al.12 found in a study on rabbits that Bio-Oss® became 
completely incorporated in newly formed bone. In comparison to three 
other bone-substitute materials (Endobon, Pro Osteon 500 and Interpore 
500 HA/CC), Bio-Oss® was found to be integrated to a higher degree in 
the surrounding bone. These findings were confirmed by other studies 
in beagles2,39. Berglundh et al.2 also concluded that Bio-Oss® becomes 
integrated and subsequently but slowly replaced by newly formed bone. 
The results of other studies are in accordance with these findings6,12,25,39. 
These characteristics of Bio-Oss® obviously are in accordance with the 
criteria of an osteoconductive m aterial2.
Platelet-rich plasma has been propagated for several years to promote bone 
healing. Still, there are contradictory reports about its clinical efficacy. For 
example, there are several studies on hum an beings showing that PRP has 
a beneficial effect on bone healing9,16,19,34,36. On the other hand, studies on 
animals revealed conflicting results, but the m ajority are rather negative1,4,7, 
14,32,33,40,42. The possible reasons for these less desirable results are discussed 
in a previous study23. In summary, the surgical site may influence the 
results. For example, in contrast w ith periosteum and dura41, respiratory 
epithelium (sinus floor elevation) can act as a resorptive endosteum43. The 
kind of bone used may also play a role, since particulate cortical bone 
proved not to heal in a predictable fashion21. In some studies, diffusion 
of PRP and/or growth factors from the experim ental to the control site 
cannot be excluded. The major reason, however, to explain the conflicting
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results may be the fact that the average concentrations of blood platelets 
used in the various studies did not take into account the great variation 
in the baseline platelet values of the animals, and thus there is variation 
in the concentration of the platelets in the PRP used. It is very relevant 
that this issue about PRP efficacy is solved, because the use of PRP is 
still associated with increased treatment cost and inconvenience for the 
patient, such as the necessity to draw blood.
W hen the current study was designed, the results of the previous study23 
were not yet known. Yet, in an attempt to reduce the amount of autogenous 
bone in reconstructive surgery, we thought it was appropriate to carry out 
a study on the use of a m ixture of an osteoconductive alloplastic material 
and particulate autogenous cancellous bone with and without PRP. Based 
on the positive reports of Berglundh et al. 19972, Clergeau et al. 19966, 
Fukuta et al. 19928, Kim et al. 200113, Valentini et al. 200038, and Wetzel 
et al. 199539, Bio-Oss® was thought to be a suitable material.
The hypothesis of the current study was that the healing of a bone 
defect filled w ith a m ixture of particulate autogenous bone and Bio-Oss® 
would be more rapid when PRP was added and that Bio-Oss® would 
be integrated in the newly formed bone. A goat model was, therefore, 
selected as previous studies at the same institution showed that a round, 
14 mm diameter, defect in  the forehead of a goat is critical sized, at least at 
twelve weeks postoperatively20. At twenty-four weeks, however, variable 
amounts of bone deposition often extending to a considerable distance 
from the m argins were observed. The dimension of the frontal bone also 
allows the preparation of 4 separate round defects in the facial part of 
each skull, which makes it possible to create two experim ental and two 
control sites for each animal. Hence, the goat model as described appears 
to be a suitable model using particulate autogenous cancellous bone23 or 
a m ixture of particulate autogenous cancellous bone and Bio-Oss® (the 
current study) to study the effect of PRP on facial bone healing.
Material and methods
In vivo study
This study was performed on twenty skeletally m ature female Saanen 
goats, weighing about 65 kg. Protocols according to the national guidelines 
for the care and use of laboratory animals were respected. Previous studies 
confirmed that the goat model used caused negligible discomfort for the
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anim als20,23 and thus, perm ission was granted by the A nim al Ethical 
Committee of the University of Nijmegen for further studies using this 
model.
Based on the method described by Clemmons et al.5 and in consultation 
with the transfusion laboratory, the currently used PRP was prepared by
the transfusion laboratory as described below. Platelets are highly (but 
reversible) activated shortly after collection of whole blood and show 
spontaneous aggregation. These aggregates disappear, however, after a 
resting period of 16-20 hours at room temperature26. These platelets have 
equal in vitro quality compared to platelets that were produced from 
whole blood that had been stored for 6 hours30. For logistic and uniform  
processing of whole blood, cooling the units to room temperature w ithin 
two hours and a subsequent storage period of about 16-20 hours until 
separation into components is preferred26. First, 250 cc of autogenous blood 
was drawn one day before surgery. This blood was treated by centrifugation 
in various cycles at the transfusion laboratory. For logistical reasons it 
was decided to perform the first spin (2000G, 10min) three hours after 
collection of the blood and to store the buffy coat and plasma separately at 
22°C. At the day of surgery 3 other cycles took place: 250 G (5 min), 3000G 
(5 min) and 3000G (5 min). After this process, plasma was removed until
10 cc were left with the rem aining platelets on the bottom of the bag. From 
this m ixture a sample was taken to count the amount of platelets. At the 
time the current experiment was performed goat platelets could not be 
automatically counted by the Coulter Onyx®, in our institute, so this was 
done with a heamatocytometer. The concentration of the platelets varied 
from 800- 1000x109/ l. Starting from a baseline value of 171 (±19,6)x109/l(5), 
a 4,2 to 6,6 fold increase of the baseline value was achieved. According 
to M arx17, a sufficient cellular response to platelet concentration begins 
when a 4 to 5 fold increase to baseline platelet numbers is achieved.
Surgery
The surgical procedure of this experiment has been previously described 
in detail23. In 20 goats four full-thickness critical bone defects20 were 
made with a hollow cylindrical trephine drill (standard outer diameter
14 mm) in the frontal bone. Dental pins (Stabilok®, Wimbledon Village, 
London) were inserted in the bone adjacent to each defect to facilitate 
orientation, one at defect A and C versus two at defect B and D each. 
Defects A and C were subsequently filled with a composite graft consisting
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of 0.3 gram of autogenous 
cancellous bone (iliac crest) 
and 0.2 gram of Bio-Oss® 
spongious granules of 1-2 
mm (Geistlich-Pharma, 
Wolhusen, Switzerland). 
The other two defects (D 
and B) were filled with 
the same composite graft 
mixed with 1 ml PRP (Fig. 
1). Therefore, the earlier 
obtained PRP suspension 
was activated at the time 
of surgery with 1 cc 10% 
calcium chloride solution 
and 300 I.U. of bovine 
thrombin (Fibriquick® 
Organon Teknica, Durham, 
US) to form a gel35, whilst 
the erythrocytes were given 
back16. After activation and 
just prior to forming a gel, 
the PRP was added (ex 
vivo) to the m ixture of Bio- 
Oss® and the autogenous 
bone particles. By doing so, 
the PRP gel was distributed 
optimally among this 
m ixture without blending, 
thus keeping the gel 
structure unimpaired.
Subsequently, the animals were divided in four groups:
Group 1 (N=5 goats; m aterials were left in place for 1 week)
Group 2 (N=5 goats; m aterials were left in place for 2 weeks)
Group 3 (N=5 goats; m aterials were left in place for 6 weeks)
Group 4 (N=5 goats; m aterials were left in place for 12 weeks)
This resulted in 10 specimen of each graft type per implantation time. At 
the end of the respective implantation times, all animals were sacrificed 
by an overdose of pentobarbital.
Fig. 1. The four experimental sites (defects) A and 
C filled with 0.3 gr. cancellous bone and 0.2 gr. Bio- 
Oss® granules (1-2 mm) B and D filled with 0.3 gr. 
cancellous bone, 0.2 gr. Bio-Oss® granules (1-2 mm) 
and 1 ml PRP each.
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Histological preparation
After sacrifice, the frontal bone of each goat was resected and stripped of 
soft tissue leaving a thin layer of connective tissue over the experim ental 
sites. These specimens were stored in a 4% phosphate-buffered 
formaldehyde solution (pH = 7.4) for fixation. After fixation, the frontal bone 
was divided in four parts, each containing one experim ental site. These 
parts were then dehydrated in graded series of alcohol and embedded in 
methylmethacrylate. After polymerisation, each part was divided in such 
a way that the experim ental site was split into two halves. One half was 
used to make three 10 ^m  transverse sections using a modified microtome 
technique15. The sections were etched with hydrochloric ethanol and 
subsequently stained with methylene blue and basic fuchsin.
Light-microscopical analysis consisted of a description of the tissue 
response w ithin the grafted area and was performed by two investigators 
using an optical microscope (Leica BV, Riiswiik, the Netherlands).
Histomorphometry
Apart from subjective 
description, each experi­
mental site was quanti­
tatively assessed using 
a grading scale for bone 
formation. Specimens 
were evaluated for:
(1) bone formation at the 
edges of the defect, and
(2) the amount of bony 
bridging of the defect 
(Table 1). Two blinded 
reviewers evaluated at 
least three sections for 
each specimen.
Categories Scores
Bone formation at the edges of the defect
None 0
One edge 1
Two edges 2
Bridging of the defect (%)
0-25 0
25-50 1
50-75 2
75-100 3
Table 1. Scoring system of bone formation at the edges 
and bridging of the defect
The reviewers reached a consensus on the score of each section and then 
assigned a final score to each specimen. The scores of the specimens of 
each m aterial group were then averaged to determine the overall score for 
the m aterial group.
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In all groups histomorphometry was also carried out on the sections to 
quantify the bone fill percentage of newly formed bone and grafted bone 
and the Bio-Oss® fill percentage in a plane perpendicular to the grafted 
area, called 'the surface of the defect'. For this purpose a Leica Qwin 
Image Processing and Analysis System (Cambridge, UK) was used. The 
sections were digitized at low magnification.
In each slide the outline of the surface of the defect was marked (Fig. 2b). 
The newly formed bone as well as the grafted bone and the Bio-Oss® 
were marked in an interactive manner. (Fig. 2c and 2d). The computer 
calculated the area of the surface of the defect, the bone surface (newly 
formed bone and grafted bone) and the surface of the Bio-Oss® particles. 
From these data the bone fill percentage and the Bio-Oss® fill percentage 
in the surface of the defect was calculated by dividing the bone surface 
area and the surface of the Bio-Oss® particles respectively by the area of 
the surface of the defect.
I— I 100 (im  I— I 100 (im
Fig. 2. Histomorphometric analysis o f a PRP-treated 14 mm defect, using both Bio-Oss® 
particles and autogenous bone particles, two weeks post-operatively. Staining: methylene 
blue and basic fuchsin. [a] The original section which was digitized at low magnification, 
[b] the outline o f the surface of the defect (blue dotted line) is depicted, [c] bony edges 
of the defect, autogenous bone particles, and newly formed bone are marked (green), [d] 
Bio-Oss® particles are marked (green). Bone fill percentage and Bio-Oss® fill percentage 
were calculated based on these observations.
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Statistical analysis
The results were statistically evaluated, the quantitative grading scale 
measurements by means of the Pearson Chi-Square test and the results 
of the histomorphometry by means of the Student t-test. Differences were 
considered statistically significant if p<0.05. Calculations were performed 
in GraphPad Instat, Version 3.05 (GraphPad Software, San Diego, CA, 
USA). All charts show error bars depicting the standard deviation.
Results
Recovery and healing were uneventful in  all goats without any signs of 
infection or wound dehiscence.
Descriptive histology
Light-microscopic exam ination of the sections revealed no differences 
between the PRP and the non-PRP group.
At one week, there was a lim ited inflam m atory reaction with sporadic 
giant cells. Fibrous tissue was rarely seen. No newly formed bone and no 
resorption of the grafted particles could be observed.
At two weeks, an increase of inflam m atory cells was seen although no 
further increase in the amount of giant cells could be observed. There 
were moderate signs of resorption of the grafted particles, marked by 
irregularities and some osteoclast-like cells, in particular around the 
autogenous bone particles. Newly formed bone was hardly visible at the 
borders of the defect, Bio-Oss® particles, and autogenous bone particles.
At six weeks, the number of inflam m atory cells had decreased considerably. 
Extensive bone formation was seen at the surface of the autogenous bone 
particles. Bio-Oss® particles show less newly formed bone compared 
to the autogenous bone particles, as shown in (Fig. 3). Because of the 
newly formed bone it was difficult to judge the amount of resorption of 
the autogenous particles. Resorption of the Bio-Oss® particles was very 
limited.
At twelve weeks, there were no signs of inflam m atory reaction. Again, 
more newly formed bone was observed in greater quantities at the surface 
of the autogenous bone particles compared to the Bio-Oss® particles. 
Sim ilar to the samples retrieved after 6 weeks, resorption of the Bio-Oss® 
particles was very limited.
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Fig. 3. Histological analysis of a PRP- 
treated 14 mm defect, using both Bio- 
Oss® granules and autogenous bone 
particles, six weeks post-operatively. 
Bony edges of the defect, autogenous 
bone particles, newly formed bone 
(pink) and Bio-Oss® particles (brown) 
are visible. There was less newly 
formed bone seen at the surface of the 
Bio-Oss® particles as compared to the 
autogenous bone particles.
Empty lacunae, caused by the absence of osteocytes, were rarely observed 
at each tim e point. Fibrous tissue was hardly ever seen in the first week. 
After two weeks, the transplanted autogenous particles and Bio-Oss® 
particles were surrounded by a fibrous tissue layer. At week six as well 
as at week twelve post-operatively, the amount of fibrous tissue remained 
the same.
Histomorphometry
Comparing the bone formation at the edge of the defect and the amount 
of bone bridging the defect, no significant differences were seen between 
the sites w ith and without PRP for the different implantation times. In all 
cases p was > 0.05 (Pearson Chi-Square test) (Table 2). Specifically, after 
one week post-operatively, no bone formation was seen at all at the edges 
of the defect. At two weeks, in five sites bone formation was seen at one
weeks
bone formation
sites
bridging of the de fec t in %
sites
examinednone 1 edge 2 edges examined 0-25 25-50 50-75 75-100
1 PRP 10 10 10 10
non PRP 10 10 10 10
2 PRP 2 8 10 6 2 2 10
non PRP 1 3 6 10 5 2 3 10
6 PRP 2 8 10 1 4 2 3 10
non PRP 1 9 10 5 2 3 10
12 PRP 1 9 10 2 3 5 10
non PRP 1 9 10 3 7 10
Table 2. Bone formation at the edges of the defect and amount of bridging of the defect.
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edge and in 14 sites at two 
edges. Bridging was seen at 
a maximum of 75% of the 
distance of the two edges 
in five cases. At six weeks, 
17 (out of 20) and at twelve 
weeks 18 (out of 20) sites 
showed bone formation at 
two edges. At six weeks 75­
100% bridging was seen in 
6 out of 20 cases, at twelve 
weeks this was the case in 
12 out of 20 cases.
With regard to the surface 
of the defect and the 
bone fill and Bio-Oss® fill 
percentages of the defect, 
no statistically significant 
differences were observed 
between the sites with and 
without PRP. All p-values 
were > 0.05 (Student t-test) 
(Fig. 4, 5, 6). Furthermore, it 
was observed that both the 
surface of the defect and 
the Bio-Oss® fill percentage 
had decreased over time 
(Fig. 4 and 6).
-C o n tro l
- P R P
Time [w eeks]
Fig.4. Histomorphometrical calculations o f the 
surface o f the defect, concerning the PRP and control 
group, after 1, 2, 6, and 12 weeks post-operatively.
-  Control 
-P R P
Fig. 5. Histomorphometrical calculations o f the bone 
fill percentage in the defect o f the PRP and control 
group, after 1, 2, 6, and 12 weeks post-operatively.
Fig. 6. Histomorphometrical 
calculations o f the Bio-Oss® 
fill percentage in the defect o f 
the PRP and control group, 
after 1, 2, 6, and 12 weeks post­
operatively.
-  Control 
-P R P
Time [w eeks]
Time [w eeks]
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Discussion
The hypothesis of this study that the addition of PRP to a mixture of 
particulate autogenous cancellous bone and Bio-Oss® in a critical size 
defect of the frontal bone of a goat will have a positive effect on early 
and late bone formation has to be rejected. The results of the histological 
and histomorphometric examinations showed that the early and late 
bone healing were not enhanced when PRP was used. These results are in 
agreement with the results from our previous study when only particulate 
autogenous bone was used23.
Plachokova et al. 200727 reported on early revascularization and newly 
formed bone at one week postoperatively using Goldner's Masson 
trichrome staining in an experiment in rats. This experiment, however, 
was done in non-critical sized cranial defects in rats using HA/beta-TCP 
(with and without PRP). Newly formed bone was observed at the defect 
borders as well as at the side of the dura. In contrast with this, in the 
present experiment the medial part of the critical sized defect was not 
formed by dura, which is osteinductive41, but by a non-osteoinductive 
respiratory epithelium which may even act as a resorptive endosteum43. 
This may explain why in the present experiment no bone formation was 
seen at one week postoperatively. The difference between the metabolism 
of small (rat) and large (goat) animals may also play a role in the rate of 
early bone healing.
The current study was based on the data as reported by Clemmons et al.5, i.e. 
that the normal platelet count in goats is 171 (±19.6)x109/l. The concentration 
of the platelets in the PRP used varied from 800-1000x109/l.
According to Marx, this increase is sufficient to stimulate cellular 
response17. Unfortunately, at the time this study was carried out, it was 
not possible to define the baseline values of each animal. This was due 
to the fact that, in goats, red blood cells are very small and, therefore, 
almost indistinguishable from platelets when using a heamatocytometer. 
Consequently, no reliable correlation between the baseline value of 
the platelets and the concentration of the platelets in the PRP can be 
determined.
According to the Merck & Co. Veterinary manual18, however, there is 
a great variation in the baseline values of the platelet numbers within 
and between species. In the various experimental studies reported, 
there is also a great variation in the concentration of the platelets in the
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PRP used1,4,7,32,40,42. In some experimental studies the concentration of the 
platelets in PRP was not mentioned at all14,33. Although, in the current 
study, the variation of the concentration of the platelets in the PRP used was 
relatively small, the preparation technique needs refinement to achieve a 
more standardized outcome, i.e. a smaller margin in the above mentioned 
variation. This variation in the concentration of the platelets may play an 
important role in the conflicting results as reported in various animal 
experimental studies using PRP. For this reason it has to be recommended 
that the critical effective amount of platelets in each sort of animal should 
be defined by experimental studies. There is also an obvious need for 
standardizing the concentration of platelets in PRP if studies are to be 
compared23.
Regarding several studies done in human beings 9,16,19,34,36 revealing a 
beneficial effect of PRP, it may be possible that human PRP is more potent 
than animal derived PRP. It should, however, be considered that the above 
mentioned studies on human beings are, for comprehensible reasons, 
not prospectively randomized, have no control sites and consist of a 
heterogeneous group of patients. A recently performed animal experiment 
in our institute by Plachokova et al.28 supports this suggestion. In this 
study, using human bone or HA/TCP in cranial critical size defects in 
nude rats, no effect of rat PRP and goat PRP was seen, whilst human PRP 
in combination with human bone caused significant more newly formed 
bone, but only after 2 weeks postoperatively. The authors note that, in 
contrast with the preparation of human PRP, the preparation of animal 
PRP can vary for different animal species. The authors also emphasize the 
importance of defining the different critical effective amounts of platelets 
and levels of growth factors in PRP for different animal species.
The second part of the hypothesis has been confirmed. The Bio-Oss® was 
integrated throughout the healing bone. This was visible at 6 and 12 weeks, 
which is in accordance with the findings of several other studies2,12,39.
The implantation sites in these studies, however, were different. The 
only comparable study using the same goat model, but without the use 
of PRP, was performed by Merkx et al.21. In this study similar frontal 
defects as in the current study were made. One defect was filled with 
particulate cancellous bone, the second with particulate cortical bone, 
the third with Bio-Oss® granules 1-2 mm, and the fourth defect was left 
empty. At twelve weeks postoperatively, the control sites were still empty 
and osteogenesis was confined only to the margins of the defects. In the
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experimental sites with particulate cancellous bone, the defects were 
totally filled with the added cancellous bone particles embedded in new 
bone. In the experimental sites with particulate cortical bone, the defects 
were not totally bridged but areas of new bone and cortical bone particles 
alternated with islands of connective tissue. In the experimental sites 
with Bio-Oss®, newly formed bone could be seen only at the edge of the 
defects with incorporated particles of Bio-Oss®. In these defects, however, 
no bone deposition at all was found in the central area where the Bio-Oss® 
particles were embedded in fibrous tissue only.
In the present study the purpose was to reduce the amount of autogenous 
bone by adding an alloplastic material, Bio-Oss®, which was supposed to 
be a reliably osteoconductive material. Based on the above mentioned 
experimental results of Merkx et al.21, using the same goat model and 
the fact that PRP is thought to be mitogenic instead of morphogenetic, 
it seemed to be of no use to add an experimental site with Bio-Oss® only 
and PRP. It has also to be noted that a particulate cortical bone graft does 
not heal in a predictable fashion in the present goat model21; therefore, 
only particulate cancellous bone without any cortical bone was added. In 
the current study, less newly formed bone was observed at the surface of 
the Bio-Oss® particles as compared to the surface of the autogenous bone 
particles. These findings confirm that Bio-Oss® is only osteoconductive. 
Without the addition of autogenous bone it can be used in small defects 
only3,29.
More interesting, however, is the obvious scaffolding effect of the Bio-Oss® 
particles in that over a period of 12 weeks they maintained the volume 
of the graft. Although the surface of the defect, reflecting the volume of 
the graft, decreased in time, the volume reduction was substantially less 
when compared with a previous experiment using the same goat model 
without the addition of Bio-Oss®23. This result confirms the observation 
of other authors that mixing autogenous bone grafts with Bio-Oss® or HA 
contributes to the maintenance of the original graft volume2,31.
It was observed that the Bio-Oss® fill percentage decreased during the 
period of healing. It may be that the particles were degraded by osteoclasts 
or became loosened over time and migrated into the surrounding soft 
tissue. Unfortunately, the surrounding soft tissue had to be removed 
before staining. Using a mixture of bone and Bio-Oss®, it was doubtful 
if demineralization of the specimen for histology could be performed 
in a predictable fashion. For this reason the specimens were embedded
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in methylmethacrylate, and the slides (10 ^m) were prepared using a 
modified microtome technique15. As a consequence, the use of different 
kinds of stains to demonstrate the presence of specific cell types was 
limited. Immunohistochemistry was also impossible as no appropriate 
antibodies for goats are available.
Wiltfang et al.40 and Thorwarth et al.37 found an initial, i.e. after two 
weeks, positive effect of a relatively high concentration of PRP on 
mineralization when only autogenous bone was used in critical size 
defects in the forehead of pigs. Using Bio-Oss® without the addition of 
autogenous bone, no beneficial effect was seen. Thorwarth et al.37 used 
an immunohistochemical analysis, which makes it possible to asses the 
expression of bone matrix proteins in relation to both static and dynamic 
parameters of bone turnover. Based on this immunohistochemical 
analysis, it was concluded that both Bio-Oss® and PRP did not have 
an osteoinductive capacity but that the osteoinductive properties of 
autogenous bone were evident. In contrast with these findings, Kim et al.13 
found a significant beneficial effect of PRP using Bio-Oss® without the 
addition of autogenous bone in critical sized calvarial defects in rabbits at 
4 and 8 weeks postoperatively. The Bio-Oss® group was compared with a 
group in which only autogenous bone was used. The rate of bone healing 
was assessed using soft x-ray contact radiographs, CT and fluorescence- 
labelled microscopy.
Plachokova et al.27 emphasized the role of the evaluation technique. They 
found newly formed bone at one week and closure of the defect after 
2 weeks in a cranial defect in rabbits using a 3-D micro-CT. At one week it 
was not possible to detect bone formation on the radiographs. The authors 
emphasize that only 3-D models based on computerized tomograms can 
visualize the final spatial distribution of the newly formed bone over 
the total defect area. This incongruity between 2-D radiographs and
3-D micro-CT reconstruction is in agreement with the findings of other 
authors11. Unfortunately, at the time the current study was carried out, no 
micro-CT equipment was available in our department.
The results presented showed no beneficial effect from the addition of 
PRP to a mixture of Bio-Oss® and autogenous cancellous bone particles. 
This may be due to the variation of the concentration of the platelets in 
the PRP used. The variation of the concentration of platelets in animal 
derived PRP may explain also why the majority of animal experiments 
using PRP to enhance bone formation with or without the addition of
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bone substitutes reveal conflicting results.
It has to be recommended, therefore, that future experimental studies 
on animals need to be carried out using standardized techniques with 
known quantities of PRP and their growth factors23,28. Unfortunately, 
there are no enzyme-linked immunosorbent assays (ELISA) available 
to measure growth factors such as TGF-|3, PDGF (AA,AB,BB), IGF-I and 
VEGF in goat PRP. For this reason, an in vitro experiment22 has recently 
been carried out preparing two standardized different concentrations 
of human PRP, i.e. 1175x109/ltr and 1750x109/ltr. The ELISA analysis 
showed that the amount of the above mentioned growth factors were 
significantly increased compared to whole human blood, but no difference 
was seen between the two different PRP concentrations. Both groups of 
PRP revealed a positive effect on the late proliferation but not on the 
differentiation of osteoblast-like cells. Using increasing dilutions of PRP, 
the tube formation by human umbical vein endothelium cells was also 
examined. It was noted that the tube length was significantly increased 
by a relatively low concentration of PRP. This may be an indication that 
the concentration of the PRP's used in many of the published studies is 
too high. The activation process of the blood platelets, i.e. by physiological 
conditions inside the body versus the forced activation of PRP, may play 
a role as well. Future (human) studies on the application of PRP would 
also benefit from a prospective randomized design, provided that this is 
ethically acceptable. Because PRP is likely to have an effect on early bone 
healing, newly developed evaluation techniques like 3-D CT can be very
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helpful studying this process.
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prp, growth fa c to r levels, e ffe c t on grow th an d  d iffe re n tia tio n : an in vitro study
Introduction
Autologous bone or bone derivatives and substitutes for jaw and 
periodontal reconstruction have significant limitations in terms of 
availability, morbidity, efficacy, immunologic reaction, and disease 
transmission. Therefore, tissue engineering is an alternative approach, 
which includes, among others, the use of a synthetic material for the 
delivery of osteogenic (osteoinductive) morphogens. Platelet-rich plasma 
(PRP) as a storage vehicle of growth factors (GFs) is a new application of 
tissue engineering and a developing area for clinicians and researchers. 
The GFs, such as platelet-derived growth factor (PDGF[AA,BB,AB]), 
transforming growth factor -|31 and -|32, platelet-derived epidermal 
growth factor (PDEGF), platelet-derived angiogenesis factor (PDAF), 
insulin growth factor-1 (IGF-1), and platelet factor-4 (PF-4) are known to 
influence bone regeneration. In addition, some authors have reported the 
presence of basic fibroblast growth factor (bFGF), epithelial cell growth 
factor (ECGF), interleukin-1 (cytokine), and osteonectin (major protein in 
mineralized bone) in the a-granules of the platelets1-4. All of this implies 
that platelet concentrates might influence bone formation through a 
variety of pathways.
The effects of PRP on osteoblast lineage have been confirmed by a few 
in vitro studies. Weibrich et al.5 observed mitogenic effects of PRP on 
osteoblast-like cells. Annunziata et al.6 and Lucarelli et al.7 showed an 
increase in growth and differentiation of PRP-treated periodontal ligament 
cells and stromal stem cells as indicated by alkaline phosphatase (ALP) 
activity and collagen type I gene expression. Additional studies revealed 
that PRP stimulated the mitogenic response of bone cells derived from 
human trabecular8 and rat bone marrow9. Yet, it is still unknown whether 
the stimulatory effects of PRP is related to the GFs present or to other 
microparticles from the cytoplasm or cell membrane that are released 
from activated platelets8.
The action mechanism of GFs is very complex, because each GF may have 
a different effect on the signal transduction of bone matrix mineralization. 
GFs may also interact with each other and consequently may form a cascade 
of different signal proteins with multiple pathways, which will ultimately 
lead to activation of gene expression followed by protein production. This 
specific characteristic of PRP, having multiple GFs, acting on multiple 
pathways, distinguishes PRP from single recombinant GFs that focus on 
a single signal transduction pathway10,11.
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However, the number of in vitro studies is very limited and additional 
questions needs to be answered. For example, animal and clinical studies 
reveal different results with the use of PRP and its effect on bone healing. 
Some researchers reported an additional effect on bone regeneration 
by using PRP in combination with bone grafts12,13; others revealed no 
differences14,15. This could be due to the differences between species, that 
is, differences in GF concentrations between species or variation in the 
presence of GFs between the various PRPs. Therefore, the aim of this 
study was to examine the presence and the concentrations of GFs in rat, 
goat, and human PRP. We examined the effect of rat PRP gel on rat bone 
marrow cells.
Material and Methods
PRP p r e p a r a t i o n
Rat PRP was obtained by drawing the whole blood of 4 male Wistar rats 
via cardiac puncture into tubes containing 3.8% sodium citrate. PRP 
was obtained from this anticoagulated blood after centrifugation at 800 
rpm for 15 min at 25°C. Three milliliters of blood resulted in 150 ^L of 
PRP. The platelets present in the whole blood and in PRP were counted 
automatically using a hematology analyser. The concentration of platelets 
obtained in the PRP was 3 times higher than the baseline. This PRP was 
used to obtain a PRP gel. The platelet concentrate was activated with a 10% 
calcium chloride solution and 300 IU of bovine thrombin. One hundred 
and fifty microliters of PRP was mixed with 25 |jL of thrombin (300 IU) 
(FibriquikTM Thrombin, Bio-Merieux, Durham, NC) together with 25 mL 
of 10% CaCl2. Goat PRP and human PRP (1 patient) were obtained from 
the Sanquin Blood bank, Nijmegen, Regio Zuid-oost. The PRP fraction 
was obtained from venous blood of 1 goat. For this reason, 250 cm3 of 
blood was drawn and centrifuged at a transfusion laboratory (Sanquin, 
Nimegen, Netherlands) in various cycles (Clemmons et al., 1983). Finally, 
10-15mL of PRP suspension was obtained. The platelet concentration was 
also counted (platelet count exceeding 1200x106/mL).
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Q u a n t i t a t i v e  s a n d w ic h  e n z y m e  im m u n o a s s a y
A quantitative sandwich enzyme immunoassay (Quantikine, R&D 
Systems Europe Ltd., Abingdon, UK) was used for examining the 
amount of TGF-|31, PDGF-AA, PDGFAB, and PDGF-BB in rat, goat, and 
human PRP. The samples were activated by adding 0.1 mL of 2.5 N 
acetic acid/10M urea to 0.1 mL of plasma. After 10 min of incubation at 
room temperature, the samples were neutralized by adding 0.1 mL 2.7 N 
NaOH/1 M N,2-hydroxyethylpiperazine-N7-2-ethanesulfonic acid (HEPES). 
The immunoassays were performed following the manufacturer's 
instructions.
Cel l  i so la t ion
Rat bone marrow (RBM) cells were isolated and cultured using the 
method described by Maniatopoulos et al.16. Femora of male Wistar rats 
were washed in culture medium a-minimum essential medium (a-MEM, 
Gibco BRL, Life Technologies B.V. Breda, The Netherlands) with 0.5 mg/mL 
of gentamycin and 3 pg/mL of Fungizone (Sigma-Aldrich, St. Louis, MO). 
Epiphyses were cut off and diaphyses flushed out with 15 mL of osteogenic 
culture medium a-MEM, supplemented with 10% fetal calf serum (FCS, 
Gibco BRL, Life Technologies B.V. Breda, The Netherlands), 50 pg/mL of 
ascorbic acid, 50 pg/mL of gentamycin, 10 mM sodium b-glycerophosphate, 
and 10-8 M dexamethasone (Sigma- Aldrich). The cells were incubated in a 
humidified atmosphere of 95% air, 5% CO2 at 37°C for 7 days. The medium 
was changed every 2 or 3 days.
Cel l  S e ed ing
After 7 days of primary culture in osteogenic medium, the pre-osteoblast- 
like cells were harvested and seeded in 24-well plates at a concentration 
of 10,000 cells/well. The tissue culture polystyrene (TCPS) wells were first 
precoated with an PRP gel (150 pL of PRP mixed with 25 pL of thrombin 
(300 IU) and mixed with 25 pL of 10% CaCl2 per well) or left uncoated. 
Cells were cultured for 16 days in the presence of osteogenic medium and 
incubated in a humidified atmosphere of 95% air, 5% CO2 at 37°C. The 
medium was changed every 2 or 3 days.
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DNA ana lysis
After 2, 4, 8, and 12 days samples were used for DNA analysis. Medium 
was removed and cell layers were washed twice with phosphate-buffered 
saline (PBS). One milliliter of MilliQ was added to each sample. The 
samples were frozen and thawed repeatedly. DNA standard curve was 
made with A DNA. One hundred microliters of sample or standard 
was added to 100 pL of Picogreen working solution (Molecular Probes, 
Leiden, Netherlands) and the samples were incubated for 10 min at 
room temperature in the dark. After incubation, DNA was measured 
using a fluorescence microplate reader (Bio-Tek instruments, Abcoude, 
Netherlands) with excitation filter 365 nm and emission filter 450 nm. The 
same samples were also used for the ALP activity assay.
ALP a c t iv i t y
ALP activity was measured at days 4, 8, and 12. For the assay (Sigma- 
Aldrich), 96-well plates were used. Eighty microliters of sample and 20 pL 
of buffer solution (5 mM MgCl2, 0.5 M 2-amino-2-methyl-1-propanol) 
were added to the wells. Subsequently, 100 pL of substrate solution 
(5 mM p-nitrophenylphosphate) was added to the wells and the plate was 
incubated for 1 h at 37°C. The reaction was stopped by adding 100 pL of 
stop solution (0.3 M NaOH). For the standard curve, serial dilutions of
4-nitrophenol were added to final concentrations of 0-25 nM. The plate 
was read in an enzyme-linked immunosorbent assay (ELISA) reader 
(Bio-Tek instruments, Abcoude, Netherlands) at 405nm.
C a lc iu m  c o n te n t
Calcium content in the samples was measured by the ortho-cresolphthalein 
complexone (OCPC) method (Sigma-Aldrich). Calcium content was 
examined at 8, 12, and 16 days of incubation. Cell layers were washed 
twice in PBS. Five hundred microliters of 0.5 N acetic acid was added to 
the wells and the samples were incubated overnight. Samples were frozen 
at -20°C until use.
OCPC solution was prepared as follows: Eighty milligrams of OCPC was 
added to 75mL of demineralized H2O with 0.5 mL of 1M KOH, 0.5 mL 
of 0.5 N acetic acid. To prepare sample solution, 5 mL of OCPC solution 
was added to 5 mL of 14.8 M ethanolamine/boric acid buffer (pH 11), 
2 mL of 8-hydroxyquinoline (5 g in 100 mL of 95% ethanol), and 88 mL of
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demineralized water. Three hundred microliters of sample solution was 
added to 10 pL of sample. To generate a standard curve, serial dilutions 
of CaCl2 were made (1-200 pg/mL). The plate was incubated at room 
temperature for 10 min and then read at 575 nm.
RNA iso la t ion
RNA was isolated from the cells with the aid of a RNA isolation kit 
(RNeasy kit, QIAGEN, Venlo, Netherlands). The cells were then disrupted 
by adding 350 pL of RLT lysis buffer. The samples were stored at -70°C until 
use. The immunoassays were performed following the manufacturer's 
instructions.
The RNA obtained was quantified by adding 1 pL of sample to 49 pL of 
RNase-free water and the absorbance was measured in a spectrophotometer 
(Bio-Rad Laboratories, Veenendaal, Netherlands) at 260 nm.
Reverse t ra n s c r ip ta s e  p o ly m e r a s e  c h a in  r e a c t io n  (RT-PCR)
After isolation of the RNA, the RT reaction was performed. One microgram 
of total RNA, 1 pL of 100ng of random primers, 1 pL of dNTP mix 
(10mM each), and 10pL of distilled water was added to a nuclease-free 
microcentrifuge tube. The mixture was heated to 65°C for 5 min and 
quickly chilled on ice. The contents of the tube were collected by brief 
centrifugation. Four microliters of 5xfirst-strand buffer (250 mM Tris-Cl, 
pH 8.3; 375 mM KCl; 15 mM MgCl2) and 2 pL of 0.1M dithiothreitol (DDT) 
were added. This was incubated at 25°C for 10 min, and the contents of 
the tube were mixed gently and incubated at 42°C for 2 min. Finally, 1 pL 
(200 U) of Superscript II (Invitrogen, Breda, Netherlands) was added and 
the mixture incubated at 42°C for 50 min. The reaction was inactivated by 
heating the mixture at 70°C for 15 min. The obtained cDNA was used as 
a template in the PCR.
Q u a n t i t a t i v e  PCR
The cDNA from the RT reaction was used as a template in PCR. To 
perform quantitative PCR, 4.5 pL of RNase-free water, 12.5 pL of SYBR® 
Green MasterMix (Eurogentec, Liege, Belgium), 5 pL of cDNA, 1.5 pL of 
reverse primer, and 1.5 pL of forward primer were added to a QRT-PCR 
96-well plate. This plate was sealed, and the Q-PCR run was performed 
with the MyiQ Single-Color Real-Time Detection System for quantification
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with SYBR® Green and melting curve analysis (Bio-Rad, Richmond, CA). 
DNA was PCR-amplified under the following conditions: 2 min at 50°C 
and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1min at 
60°C, with data collection in the last 30s. The reference household gene 
used to normalize the amount of mRNA in the cultures was GAPDH 
(ACt= CTgene of interest - Ctgapdh [1]). Gene expression was measured relative to 
the gene expression of cultures on the relevant substrates (PRP gel-coated 
or uncoated TCPS) that had not received antibodies, after day 1 of culture 
(AACt = ACTsample- ACTcontrol [2]). The-fold change in gene expression relative 
to the control was calculated via 2-AAct (3)17.
Stat is t ica l  ana lys is
This study was performed using 2 separate runs of experiments. In each 
run, samples were present in quadruple. In the Results section, data of 
both runs are described but only the first run is presented in the figures. 
Statistical analysis was performed for each run by using an unpaired t- 
test (GraphPad Software, San Diego, CA).
Results
Presence a n d  q u a n t i f i c a t i o n  of  GFs in rat, g o a t  a n d  h u m a n  PRP
The concentrations of GFs — TGF-|31, PDGF-AA, PDGF-BB, and PDGF-AB 
— in rat, goat, and human PRP were examined. Rat PRP was prepared by
1 centrifugation step and resulted in a 3-fold increase of platelets above 
baseline (rat PRP = 3000x106/mL). Human and goat PRP were prepared in
2 centrifugation steps and resulted also in a 3-fold increase for goat and 
6-fold increase for human in platelets above baseline (goat and human 
PRP=1200x106/mL). As shown in Table 1 and Fig. 1, various GFs were 
tested and different concentrations of GFs were obtained in rat, goat, and 
human PRP. For TGF-|31, 7.8 ng/mL was detected in rat PRP, 53 ng/mL 
was detected in goat PRP, and 2.6 pg/mL was detected in human PRP. For 
PDGF-AA, 9.7 pg/mL was detected in rat PRP, 561 pg/mL was detected 
in goat PRP, and 7.9 ng/mL was detected in human PRP. For PDGF AB, 
10 pg/mL was detected in rat PRP, 108 pg/mL was detected in goat PRP, 
and 76.4 ng/mL was detected in human PRP. For PDGF-BB, 590 pg/mL was 
detected in rat PRP, 39 pg/mL was detected in goat PRP, and 66 ng/mL was 
detected in human PRP.
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Growth
factor PRP Concentration (pg/mL)
TGF-(31 Rat 7767
Goat 52,917
Human 2,580,000
PDGF-AA Rat 9.73
Goat 561
Human 7916
PDGF-AB Rat 10
Goat 108
Human 76,417
PDGF-BB Rat 590
Goat 39
Human 66,083
Table 1. Concentrations o f the GFS TGF-fi1, PDGF-AA, -AB, and -BB in rat, goat and 
human PRP.
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1.000.000 
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□  rat
□  goa t
□  human
TGF-P1 PDGF-AA PDGF-AB PDGF-I
Fig. 1. Concentration o f the GFs TGF-fi1, PDGF-AA, -AB and -BB in rat, goat, and 
human PRP.
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Effect of  rat PRP g e l  on rat b o n e  m arrow  cel ls
The DNA results 
showed that PRP 
stimulated the initial 
cell growth significantly 
at days 2 and 4 ( p<0.05).
A linear growth curve 
for uncoated control 
samples was observed.
In contrast, the coated 
samples showed a linear 
growth from day 2 to 4, 
a steady state from day
4 to 8, and a decrease in 
DNA from day 8 to 12
(Fig. 2).
Fig. 2. Cell growth o f rat bone marrow cells cultured 
on PRPcoated and noncoated wells (1st run)
□  PRP min
□  PRP plus
Fig. 3. ALP activity o f rat bone marrow cells cultured 
on PRPcoated and noncoated wells (1st run).
A negative effect of PRP 
on the ALP activity could 
be observed at days 4, 8, 
and 12. The ALP activity 
of the control samples 
showed an increase of 
activity from day 4 to 8 to 
12 while the PRP-coated 
samples showed an ALP 
activity at a constant low 
level (Fig. 3).
A significant increase in calcium content was found at days 8, 12, and 
16 for the samples coated with PRP compared to the uncoated samples 
( p<0.05). The uncoated samples showed only a low amount of calcium 
at day 16 (Fig. 4). Real-time PCR was performed to get some additional 
data about the gene expression of certain osteogenic markers. The results 
showed that PRP down regulated ALP and bone sialoprotein at days 1 
and 8. It down regulated osteocalcin at day 8 and down regulated collagen 
type I at day 1. However, PRP up regulated osteocalcin at day 1 and up 
regulated collagen type I at day 8 (Fig. 5).
82
prp, growth fa c to r levels, e ffe c t on grow th an d  d iffe re n tia tio n : an in vitro study
Fig. 4. Calcium 
content o f rat 
bone marrow cells 
cultured on PRP- 
coated and noncoated 
wells (1st run).
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Fig. 5. The relative quantity o f mRNA (%) o f ALP (alkaline phosphatase), OCN 
(osteocalcin), Coll (collagen type I) and BSP (bone sialoprotein). The so-called 2-AACT 
method was used to evaluate the differences in gene expression between uncoated (PRP 
min) and PRP coated samples (PRP plus). All CT values were normalized to the CT values 
o f the house-keeping gene GAPDH. Second, the ACT values o f PRP were normalized to 
the ACt values o f the control group, the uncoated samples. Finally, the 2-AACT values o f the 
control group were called 100% while the 2-AACT values o f the PRP coated groups were 
multiplied with 100%.
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Discussion
The results of our immunoassays revealed that human PRP contained 
higher concentrations of GFs per platelet as compared to rat and goat PRP 
Goat PRP showed also higher concentrations of GFs per platelet compared 
to rat PRP except for PDGF-BB, which had a higher concentration in rat 
PRP. TGF-|31 was the most abundant GF in all 3 PRPs. As of yet no data are 
available about the differences among rat, goat, and human PRP. Apart 
from animal studies with successful outcomes for PRP, there are also 
contradictory results in which no benefit of PRP was found3,18. The present 
results can probably explain why it is currently very difficult to obtain a 
beneficial effect of PRP in experimental animal studies. The PRP applied 
was always prepared from blood of the experimental animals, while no 
data were available about the amount of platelets that need to be used in 
the studies. This could be species-related because of the differences in 
concentrations of the GFs in PRPs obtained from rat, goat, and human. 
Only a few studies have reported on the synergistic effects of multiple 
GFs in a defective site. There are still many questions to be answered 
before the exact mechanism of the action of PRP can be fully explained.
According to Marx et al.1, human PRP is an autologous concentration of 
human platelets above baseline in a small volume of plasma. Normal 
platelet counts in human blood range between 150x106/mL and 350x106/ 
mL with an average of about 200x106/mL. A concentration of 1000x106/mL 
in a 5 mL volume of plasma could be the working definition of human 
PRP. Platelet concentrations of less than 1000x106/mL were not reliable 
to enhance wound healing, whereas higher concentrations did not show 
further enhancement of wound healing19. Weibrich et al.20 examined the 
platelet concentration among different human donors and discovered 
that the platelet concentration of the human PRP, prepared in a blood 
bank, correlated with the platelet count in the donor whole blood. They 
found also a significant influence of gender on platelet concentration, but 
no influence of age. On the other hand, Paques et al.21 demonstrated that 
the concentrations of the GFs present in human platelet lysates were not 
related to donor origin. Regarding the required platelet concentration for 
PRP efficiency, Haynesworth et al.22 showed that the proliferation and 
differentiation of adult mesenchymal stem cells were directly related to 
the platelet concentration. They showed a dose-response curve indicating 
that a sufficient cellular response to platelet concentrations first began 
when a 4- to 5-fold increase over baseline platelet numbers was achieved. 
Platelet concentrations ranged from 800 to 1200x106 platelets/mL have
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been proposed to be effective by Weibrich et al. and Fennis et al.23,24. As 
most individuals have a baseline blood platelet count of 200±75x106/mL, a 
platelet count of 1000x106/mL as measured in a volume of 5mL plasma can 
be the ''therapeutic dose'' of PRP2,25. The PRP formulations that were used 
in our study had a 3-fold increase for rat and goat and a 6-fold increase for 
human PRP; that is, rat PRP had a concentration of 30 00x106/mL (whole 
blood 1000x106/mL), goat PRP had a concentration of 1200x106/mL (whole 
blood 400x106/ mL) and human PRP had a concentration of 1200x106/mL 
(whole blood 200x106/mL).
The present study revealed that PRP had a stimulating effect on the initial 
cell growth and matrix mineralization of rat bone marrow cells. This is in 
agreement with Lucarelli et al.7 and Weibrich et al.5, who also observed 
increased cell growth and differentiation with osteoblast-like cells and 
stromal cells. Soffer et al.26 observed in a study with fetal rat calvarial cells 
that short-term exposure (24 h) of PRP to the cells stimulated the growth 
and differentiation of these cells. However, a long-term exposure resulted 
in a decrease in both ALP activity and mineral formation. Choi et al.27 
and Arpornmaeklong et al.28 showed in their study that the viability and 
proliferation of alveolar bone cells obtained from mongrel dogs and rat 
bone marrow cells were suppressed by high PRP concentrations, but were 
stimulated by low PRP concentrations. Arpornmaeklong et al.28 observed 
also that the cell differentiation of rat bone marrow cells was suppressed 
with a high concentration of PRP. In the present study, the well plates 
were coated with a PRP gel. Therefore, the cells probably experienced a 
short-term exposure of GFs. As known from other studies the life span 
of a platelet in a wound and the period of direct influence of its GFs is 
less than 5 days in in vivo situations29. After the initial burst of GFs, the 
platelets synthesize and secrete additional GFs for the remaining days 
of their life span. However, it can be questioned whether this same GF 
release pattern will occur in an in vitro situation. Tsay et al.30 showed in 
their in vitro study that PRP gels had a burst release of 80% of PDGF-AB 
and 82% of TGF-|31 in the medium after 24 h and a sustained release for 
another 14 days.
Additional studies revealed that PRP stimulated the mitogenic response 
of bone cells derived from human trabecular8 and rat bone marrow9. Yet, 
it is still unknown whether the stimulatory effects of PRP is related to 
the GFs present or to other microparticles from the cytoplasm or cell 
membrane that are released from activated platelets8. However, our ELISA 
results and also Soffer et al.26 showed that appropriate amounts of GFs can
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be detected. Previous in vitro studies with single GFs, such as TGF-|31, 
showed already that concentrations of 5-10 ng/mL in rat bone marrow 
cell cultures result in increased cell proliferation with no effect on cell 
differentiation31. Other authors reported that the single GFs PDGF-AA and 
BB enhanced cell proliferation of bone cells (10 ng/mL)10,32,33. Antibodies 
against PDGF appeared to decrease the mitogenic activity of human bone 
cells with PRP8.
Real-time PCR results showed a down regulation for the ALP gene when 
PRP was used as the coating. This is in keeping with our ALP activity 
results, which showed a decrease in activity with PRP, while more calcium 
content was measured with PRP-coated samples. In accordance with the 
calcium results, the PCR results showed an up regulation for the genes 
osteocalcin (as a marker for the osteoblast phenotype) and collagen type I 
(as a marker for matrix mineralization).
The present study also contains some limitations. Rat PRP was obtained 
from 6 rats and was used for rat bone marrow cell culture and GF 
quantification, but the human and goat PRP samples for GF quantification 
were taken from 1 patient or 1 animal. Therefore, we cannot generalize the 
results obtained from GF quantification because of the large intraspecies 
variations.
Conclusion
On the basis of our results, we conclude that PRP contains osteoinductive 
GFs, which are probably species related. However, we cannot generalize 
the results because of the large intraspecies variations. Further, we 
conclude that rat PRP gel stimulates the initial growth and differentiation 
of rat bone marrow cells in vitro. Evidently, PRP has the potential to be an 
osteoinductive factor for GF-based tissue engineering.
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INTRODUCTION
Growth factors released by activated platelets are supposed to have a 
stimulating effect on several kinds of cells as involved in initial bone 
(wound) healing, for example osteoblasts, endothelium cells, fibroblasts 
and mesenchymal stem cells. The basic hypothesis of adding PRP to bone 
grafts, is that high concentrations of the released growth factors enhance 
the initial wound healing response1,2,3.
After the introduction of PRP as a strategy to enhance bone healing, 
several clinical and experimental studies have been carried out. Some 
of the clinical studies reported good results when PRP was added to an 
autogenous bone graft4,5,6,7. In all these studies, human PRP was used in 
variable concentrations. In order to test the validity of the addition of PRP 
to bone grafts, also many experimental animal studies have been carried 
out, but the results of these studies are not consistent and contradictory
outcomes have been reported8,9,10,11,12,13,14,15,16,17 . A minority of these studies
showed a beneficial effect of PRP on the healing of the bone defect10,14,17. 
These results are certainly difficult to explain, particularly in the light of 
the mainly positive results of a large number of in vitro studies. To the 
best of our knowledge, 38 in vitro studies on the use of PRP have been 
published over the last eight years. Of these 38 studies, 31 (81,5%) (24 with 
human PRP and 7 with animal PRP) reported significant positive effects 
of PRP on the proliferation rate of osteoblasts or osteoblast-like cells 
and mesenchymal stem cells1,18-47. In seven of these studies, a significant 
increase of the proliferation rate was observed when PRP was used in a 
relatively low concentration (range 12x109/l -  280x109/l). It was observed 
that higher concentrations of PRP caused a decrease in cell proliferation23,26,28, 
33344i46. Slapnicka et al.48 tested eight different concentrations of PRP (range
0.38-2,86 times the base line value) and found no significant positive effect 
at all on the proliferation rate of human osteoblasts. In eight studies20,27,30,31, 
32,34,44,45 differentiation of the various cell types used was noted, but six 
other studies did not reveal any differentiation at all21,36,39,40,43,47. In the
studies mentioned, however, different experimental set-ups were used,
1.e. variation in cell origin, seeding density, temporal sampling, PRP 
preparation procedures and platelet concentrations. Comparisons are, 
therefore, difficult to make and conclusions impossible to draw. On top of 
that, most studies draw conclusions from average PRP-concentrations that 
were retrospectively calculated from the average base line values. This is 
a meaningless exercise due to the variety in the base line values and PRP- 
concentrations. This effect can be enhanced by potential dose-dependent
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effects of PRP and its growth factors, which may vary for different animal 
species and even individual animals/humans.
In order to learn more about the clinical efficacy of PRP, an in vitro study 
was designed to obtain information on the effect of various concentrations 
of human PRP. The target cells were rat osteoblast-like cells and human 
endothelium cells. The various assays were performed with standardized 
PRP-derivatives. The hypothesis was threefold:
• The concentration of growth factors increases with an increase of 
the platelet concentration.
• Platelet concentrations of five-fold the average base line value or 
five-fold the maximum base line value both have an effect on target 
cells behaviour.
• A platelet concentration of five-fold the maximum base line value 
has a more profound effect on target cell behaviour than a platelet 
concentration of five-fold the average base line value.
MATERIAL AND METHODS
PRP p r e p a r a t i o n
Human whole blood from ten healthy male individuals was collected in 
sterile tubes using acid-citrate dextrose-A as a anticoagulant and platelet 
concentrates were prepared for clinical use by the Sanquin Blood bank, 
Nijmegen, the Netherlands. The whole blood donated was processed, 
separating platelets from red blood cells and leucocytes by means of 
cytapheresis. Informed consent was obtained from all individuals to use 
the remnants of these platelet concentrates for the current in vitro study. 
By centrifugation and subsequent dilution, using the remnants of the 
platelet concentrates, from each donor two different PRP's were prepared; 
both representing a different (standard) concentration of platelets. Both 
PRP's were obtained independent of the individual baseline value of 
platelets. For the first PRP (PRPlow), it was the goal to achieve a platelet 
concentration of ~1175x109/l, which is approximately five times the average 
number of platelets in peripheral human blood. For the second PRP 
(PRPhigh), it was the goal to achieve a platelet concentration of ~1750 x109/l, 
which is approximately five times the maximum number of platelets in 
peripheral human blood. The platelet-numbers in the PRP's and in whole 
blood were counted automatically by a haematology analyser (ADVIA120, 
Siemens Healthcare Diagnostics). The PRP's and whole blood were then
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activated by adding calcium chloride and Fibriquik™ (Thrombin Reagent, 
bioMerieux, Inc, Durham, USA) to the blood product in the ratio 1:1:6 (v/v/v), 
following the manufacturer's protocol. Clots were allowed to retract for 
30 min. After that, a centrifugation step was carried out at 4000 RPM 
for 10 min at 22°C to separate the supernatant, containing the growth 
factors, from the aggregated platelets. The supernatants were stored at 
-80°C. The supernatant of both PRP's was called PRP-derivative, andlow
PRP-derivativehigh respectively.
D e te rm in a t io n  of  g ro w th  fa c to r  levels
Samples of all ten donors (whole blood and prepared PRP-derivatives) were 
subjected to enzyme-linked immunosorbent assays (ELISA; Quantikine®, 
R&D Systems Europe Ltd., Abingdon, UK) for measuring the amount of 
human PDGF-AA, PDGF-AB, PDGF-BB, TGF-|31, IGF-I, and VEGF. The 
immunoassays were performed following the manufacturer's instructions 
and the minimal detectable dose of these growth factors with the used 
ELISA-test were: PDGF-AA: 2.29pg/ml, PDGF-AB: 1,7pg/ml, PDGF-BB 
<15pg/ml, TGF-|31: 4,61pg/ml, IGF-I: 0,026ng/ml and VEGF: <9,0pg/ml. 
All samples were analysed in duplicate, after which the absorbance 
was measured at 450nm (EL800 Universal Microplate Reader, Bio-Tek 
Instrument, Inc.,Vermont, USA).
Cel l  cu l tu re  
Osteoblast-like cell culture experiment
Rat bone marrow (RBM) cells were isolated and cultured using the method 
described by Maniatopoulos et al.49. Briefly, the two femora of a male 
Wistar rat (40-43 days old) were retrieved and washed in wash medium 
(a-MEM, Gibco BRL, Life Technologies B.V. Breda, the Netherlands) 
supplemented with 0.5mg/ml gentamycin and 3 pg/ml fungizone (Sigma- 
Aldrich, St. Louis, MO). Epiphyses were cut off and diaphyses were 
flushed with 10 ml of osteogenic medium (a-MEM, supplemented with 
10% foetal calf serum (FCS, Gibco BRL, Life Technologies B.V. Breda, the 
Netherlands), 50 pg/ml ascorbid acid (Sigma-Aldrich Inc, St. Louis, USA), 
10 mM |3-glycerophosphate, 10'8 M dexamethasone (Sigma-Aldrich), and 50 
pg/ml gentamycin. The isolated cells were cultured in osteogenic medium 
in three 75 cm2 culture flasks (Greiner Bio-one GmbH, Frickenhausen, 
Germany) in a humidified atmosphere of 95% air, 5% CO2 at 37°C (IG 
650/750, JOUAN S.A., Saint-Herblain, France). The osteogenic medium
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was changed every 2 or 3 days. After 7 days of pre-culture, the obtained 
osteoblast-like cells were used for the cell culture experiments, which 
was carried out in two independent runs in triplicate (n=3). For each run, 
freshly-isolated cells were used.
Cell seeding
After 7 days of primary culture in osteogenic medium, the osteoblast-like 
cells were trypsinized, harvested, counted and finally seeded in 24-well 
plates at a concentration of 10,000 cells/cm2. Four experimental conditions 
were created:
1. Negative control (basic medium: a-MEM + 10% FCS + gentamycin);
2. PRP-derivative, (basic medium enriched with PRP-derivative, );low low
3. PRP-derivativehigh (basic medium enriched with PRP-derivativehigh);
4. Positive control (osteogenic medium)
The PRP-derivatives used in the cell culture experiment consisted of 
volumetrically pooled PRP-derivatives of the individual donors to 
assure sufficient volumes for stimulation in the cell culture experiments. 
Addition of PRP-derivatives was carried out at days 1, 4, and 7 after cell 
seeding by adding 10 volume% (v/v) of the respective PRP-derivative to 
basic medium. This procedure allows potential stimulation of the cells 
by the PRP-derivatives for a period up to 10 days. Cells were cultured 
in a humidified atmosphere of 95% air, 5% CO2 at 37°C with 3 medium 
refreshments per week.
Cel l  p ro l i fe ra t io n
Cell proliferation was measured by determination of cellular protein 
content in individual wells (n=3) for each experimental group. At 4, 8,
12, 16 and 24 days post-seeding, the medium was removed and the cells 
were washed with phosphate-buffered saline (PBS; pH 7.4). Subsequently,
1 ml milliQ was added. Samples were frozen and thawed for 3 repetitive 
cycles, after which the cellular protein content was determined using a 
micro BCA protein assay (Pierce, Rockford, IL, USA) according to the 
instructions of the manufacturer.
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ALP analysis
Alkaline phosphatase activity was measured as a marker for early 
differentiation of osteoblast-like cells using the same samples (n=3) as for 
the proliferation assay according to a previously described method50. A 
volume of 80 pl of sample or standard and 20 pl of buffer solution (5 mM 
MgCl2, 0.5 M 2-amino-2-methyl-1-propanol) was pipetted into a 96-wells 
plate (Greiner Bio-One) in duplicate and 100 pl of substrate solution (5 
mM paranitrophenylphosphate) was added per well. Subsequently, the 
plate was incubated for one hour at 37°C, after which the reaction was 
stopped by adding 100 pl 0.3 M NaOH. Serial dilutions of 4-nitrophenol 
(final concentrations: 0 -  25 nM) were used for the standard curve. The 
plate was read in an ELISA reader at 405 nm.
Calcium content
The deposition of calcium was used as a marker of late differentiation 
of osteoblast-like cells. The amount of calcium deposited after 4, 8, 12,
16, and 24 days of cell culture was measured by the orthocresolphtalein 
complexone (OCPC) method (Sigma), as described previously51. Briefly, 
the cells were washed twice using PBS, after which 1 ml 0.5 N acetic acid 
was added to each of three wells per experimental group (n=3). After 
overnight incubation on a shaking apparatus, 300 pl working solution was 
added to 10 pl sample of standard in a 96-wells plate (Greiner). Working 
solution consisted of (a) OCPC solution (80 mg OCPC in 75 ml milliQ +
0.5 ml 1 M KOH + 0.5 ml 0.5 N acetic acid), (b) 14.8 M ethanolamine/boric 
acid buffer (pH 11), (c) 8-hydroxyquinoline (1 g in 20 ml 95% ethanol), and 
(d) milliQ, in a ratio 5:5:2:88 (a:b:c:d). A standard curve was generated by 
preparing serial dilutions of CaCl2 (range: 0 -  100 pg/ml).
Morphological analysis
Scanning electron microscopy (SEM) was used to analyse cell morphology. 
For this purpose, cells were seeded on Thermanox® Coverslips (13mm 
dia, Rochester, NY, USA) in 24-well plates. Samples (n=2) were prepared 
after 4 and 16 days of cell culture by washing twice with PBS, incubation 
in glutaraldehyde (2%) for 10 min, washing with 0.1 M cacodylatebuffer, 
and incubation in a graded series of ethanol for dehydration. Finally, the 
samples were dried with tetramethylsilane (ACROS organics, New Jersey, 
USA), sputter-coated with gold and analysed using a JEOL 6310 SEM.
99
ch a p te r 5
Endo the l iu m  c e l l  e x p e r im e n t  
Culture of endothelium cells
Human umbilical vein endothelium cells (HUVECs) were obtained cryo- 
preserved from BDTM Biosciences (BDTM Biosciences Discovery Labware, 
Erembodegem, Belgium). Cells were cultured in 75 cm2 culture flasks in 
Medium-200 (Cascade Biologics, Portland, USA), supplemented with LSGS 
(Low Serum Growth Supplement; containing 1 mg/ml hydrocortisone, 1.5 
pg/ml bFGF, 5 mg/ml heparin, 100 pg/ml BSA, gentamycin/amphotericin
B, 5 pg/ml EGF and 2% foetal bovine serum) and incubated in a humidified 
atmosphere of 95% air, 5% CO2 at 37°C until 80% confluence.
Tube-formation assay
The effect of various dilutions of the PRP-derivates on the tube-formation 
capacity of human umbical vein endothelium cells (HUVEC, BDTM 
Biosciences Discovery Labware, Erembodegem, Belgium) was studied 
using a commercially available tube-formation assay (BD BioCoatTM 
Angiogenesis Plates, 96-well format; BD Biosciences Discovery Labware, 
Bedford, USA) and HUVECs of passage 2 or 3. The assay was performed 
following manufacturer's instructions (Guidelines for Use, BD BioCoatTM 
Angiogenesis System Endothelial Cell Tube Formation, Version 3.0), 
except for the staining and measuring. HUVECs were seeded at 20x103 
cells/well, and the experimental conditions enrolled in the tube-formation 
assay consisted of increasing volume% of pooled PRP-derivatives. Based 
on the results of a preliminary experiment with range 5-50% (v/v), which 
revealed a significant decrease of tube formation when the volume% was 
> 20%, a range of 2-20% was used to obtain more detailed information 
about the most effective concentration(s). The positive control consisted 
of VEGF-supplemented medium (20 ng/ml; recombinant rat VEGF, 
rrVEGF164, Dept. Biochemistry, Radboud University Nimegen Medical 
Centre, Nimegen, the Netherlands). The plates were incubated in a 
humidified atmosphere of 95% air, 5% CO2 at 37°C for 18 hours. Following 
incubation, medium was carefully removed from the plates and the 
plates were washed twice with HBSS (Hank's Balanced Salt Solution, 
CaCl2 and MgCl2, Gibco®, Invitrogen™, Paisly, U.K.) by adding 100pL of 
HBSS to each well. Subsequently, digital images were made of each well 
using a Leica DC-200 digital camera (LEICA Microscopy Systems Ltd., 
Heerburg, Germany) mounted on a Leica Leitz DM IL microscope (Leica 
Mikroskopie & Systeme GmbH, Wetzlar, Germany) at a magnification of 
40x (Leica 519 750 Periplan 10x/18 and Leitz Wetzlar 519759 EF 4/0.12,
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Germany). Images were analysed manually with Leica QWin software 
(Leica Microsystems, Germany) for the parameters 'total tube length' and 
'number of connections'. The tube-formation assay was carried out with 
at least 5 samples per experimental group (n=5).
Stat is t ical  ana lys is
Results of the platelet count and cell culture experiment were statistically 
evaluated using a one-way analysis of variance (ANOVA), followed by a 
post-hoc Tukey-Kramer Multiple Comparisons Test. Results of the tube 
formation assay were statistically evaluated, using a one-way analysis of 
variance (ANOVA), followed by a post-hoc Dunnett Multiple Comparisons 
Test. The significance level for both tests was set at p<0.05. Calculations 
were performed in GraphPad Instat, Version 3.05 (GraphPad Software, 
San Diego, CA, USA).
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Figure 1. Concentration o f growth factors (x 103 picogram/ml) PDGF-AA, PDGF-AB, 
PDGF-BB, TGF-fi1, IGF-I and VEGF in human PRP-derivatives. Bars represent means 
± SD o f triplicate samples. * P<0.05, ** P<0.01 and *** P<0.001 compared to whole 
blood.
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Results
PRP-charac ter iza t ion  
Platelet count
Platelet counts of whole blood and both PRP's of each individual donor 
are depicted in Table 1. Platelet counts in whole blood ranged from 116 to 
462x109/L, with an average of 236±98x109/L. Platelet counts of both PRP's 
were significantly higher compared to whole blood (p<0.001): PRPlow averaged 
1181±104x109/L (range: 971-1351x109/L); PRPhi h averaged 1879 ±w125x109/L 
(range: 1780-2072x109/L). Platelet counts in PRPhigh were also significantly 
higher compared to PRPlow (p<0.001).
Growth factors level
Level of various growth factors (PDGF-AA, PDGF-AB, PDGF-BB, TGF-|31, 
IGF-I, and VEGF) was measured using enzyme-linked immunosorbent 
assays (ELISA). The mean growth factor levels (averaged from the levels 
of each individual donor) in whole blood and both PRP-derivatives 
are presented in Figure 1. All measurements were above the detection 
limits.
Table 1. Platelet counts (x 109/L) 
fo r  each human donor (n=10) 
in whole blood and both PRP's 
(PRPlow and PRPhigh). Mean 
and standard deviation (SD) 
are given below the values of 
each individual donor. The mean 
platelet counts fo r  the three 
preparations are significantly 
different (p<0.001).
Platelet number (x1 09/L)
Donor
whole
blood
PRPlow PRPhigh
1 204 1111 1741
2 275 971 1926
3 146 1230 2072
4 203 1226 2006
5 116 1224 1833
6 223 1215 1780
7 462 1351 unknown
8 225 1151 unknown
9 185 1153 1796
10 316 unknown unknown
Mean 236 1181 1879
SD 98 104 125
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Figure 2. Cellular protein concentrations (pg/ml) in primary rat osteoblast-like cell 
cultures fo r  positive controls (osteogenic medium), negative controls (basic medium) and 
PRP-derivative supplemented media. Bars represent mean ± SD o f triplicate samples. * 
p<0.05, **p<0.01, *** and p<0.001 compared to positive controls.
Day 4 Day 8 Day 12 
Time (days)
Day 16 Day 24
■ Negative 
PRP-derivative low
■ PRP-derivative high
Figure 3. ALP-activity (nmol 4-NP/h/pg cellular protein) in primary rat osteoblast-like 
cell cultures fo r  positive controls (osteogenic medium), negative controls (basic medium) 
and PRP-derivative supplemented media. Bars represent mean ± SD o f triplicate samples. 
**p<0.01, *** and p<0.001 compared to positive controls.
104
prp, e ffe c t on rat osteob last-like  cells an d  hum an endo th e lium  cells: an in vitro study
Significant differences were observed for both PRP-derivatives compared 
to whole blood for PDGF-AA (PRP-derivativelow p<0.01; PRP-derivativehi h 
p<0.001), PDGF-AB (p<0.01), and TGF-|31 (p<0.001). Additionally, Pr P- 
derivativehigh showed significantly higher levels of VEGF compared to 
whole blood (p<0.01). For PDGF-BB and IGF-I, no statistically significant 
differences were measured between the three different groups (p>0.05). 
No significant differences were observed between both PRP-derivatives.
Cel l  c u l tu re  e x p e r im e n t  -  O s te o b la s t - l i ke  cel ls
Two separate runs of the cell culture experiment with primary osteoblast­
like cells were carried out, which showed similar results for proliferation, 
differentiation, mineralization, and morphology. The details of one 
representative run are presented below.
Proliferation (Figure 2)
Total cellular protein levels were measured after 4, 8, 12, 16 and 24 
days of culture. Compared to the positive controls, PRP-derivative 
supplementation significantly increased cell proliferation at day 12 
(p<0.001), day 16 (PRP-derivativelow p<0.05; PRP-derivativehigh p<0.01), 
and day 24 (p<0.001). In contrast, negative controls showed significantly 
decreased cell proliferation at day 8 (p<0.001) and significantly increased 
cell proliferation at day 24 (p<0.001) compared to positive controls.
Differentiation (Figure 3)
ALP activity was measured as a marker for osteoblast-like cell 
differentiation. Compared to positive controls, PRP-derivative 
supplementation significantly decreased ALP-activity at day 12 (p<0.001) 
and day 24 (PRP-derivativelow p<0.01; PRP-derivativehigh p<0.001). Negative 
controls showed significantly decreased ALP-activity at day 24 (p<0.01) 
compared to positive controls.
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Mineralization (Figure 4)
The deposition of calcium in the mineralized extracellular matrix by 
primary rat osteoblast-like cells was used as a late marker of differentiation. 
Compared to positive controls, PRP-derivative supplementation 
significantly decreased mineralization at day 16 (p<0.01) and day 24 
(p<0.001). Additionally, negative controls showed significantly decreased 
mineralization at day 16 (p<0.01) and day 24 (p<0.001) compared to positive 
controls.
Morphology analysis
After 4 and 16 days, the morphological appearance of the different 
experimental cell cultures were analysed using SEM. At day 4, no calcium 
deposition could be seen for all groups. Osteoblast-like cells were covering 
parts of the surface. At day 16, calcium deposition could be seen in the 
positive control groups in the form of mineralized nodules. Some collagen 
bundles were also seen in this group. Both PRP-derivative supplemented 
groups showed calcium deposition, though substantially less compared to 
the positive control group. Moreover, no apparent differences in calcium 
deposition could be seen between the two PRP-derivative supplemented 
groups. In the negative control group, no mineralized nodules could 
be observed. Electron microscopy images from day 16 are depicted in 
Figure 5.
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Figure 4. Calcium deposition (p.g/ml) in primary rat osteoblast-like cell cultures for  
positive controls (osteogenic medium), negative controls (basic medium) and PRP- 
derivative supplemented media. Bars represent mean ± SD o f triplicate samples. **p<0.01, 
*** and p<0.001 compared to positive controls.
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Figure 5. Scanning electron micrographs o f rat bone marrow cells at day 16. Graphs are 
shown for the groups: positive controls (A 750x / B 4000x), negative controls (C 750x / D 
4000x), PRP-derivativelow (E 750x / F 4000x), PRP-derivativehigh (G 750x / H 4000x).
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Cel l  c u l tu re  e x p e r im e n t  -  En do the l iu m  cel ls
Primary human umbilical vein endothelium cells (HUVECs) were cultured 
with supplementation of VEGF (20 ng/ml; control) or PRP-derivatives 
(various volume%; range 2 -  20%). Different volumes of PRP-derivatives 
cause dilutions corresponding to different concentrations of platelets per 
experimental group PRPlow and PRPhigh respectively (Table 2). After 18 
hours of incubation, light microscopy images were obtained (Figure 6), 
which were subsequently used to determine the parameters 'tube length' 
and 'number of connections'.
Microliters of PRP-derivative 
per 1 0 0  jul of ce ll suspension 
(volume%)
Corresponding number of platelets (x109/l)
PRP,ow PRPhigh
2 23,5** 35**
5 58,8** 87,5**
8 9 4 ** 140**
1 0 117,5 175
1 2 141 2 1 0
15 176,3 263
18 211,5 315
2 0 235 350
30 352,5 525
40 470 700
50 587,5 875
Peripheral blood; mean [platelet] 236 x 109/l
Table 2. Different volumes o f PRP-derivatives causes dilution corresponding with different 
concentrations o f platelets per experimental group. Positive significant results o f the 
experimental groups PRPlow and PRPhigh in both tube formation assays are depicted by **. 
**: P<0.01 is calculated for  each experimental group compared to control.
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Figure. 6. Tube-like structures are shown for  the groups: control with VEGF (A/B), 
PRP-derivativelow 2% (C), PRP-derivativehigh 2% (D), PRP-derivativelow 5% (E), 
PRP-derivativehigh 5% (F), PRP-derivativelow 8% (G), PRP-derivativehigh 8% (H), 
PRP-derivativelow 10% (I) and PRP-derivativehigh 10% (J).
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Tube length (Figure 7)
Compared to controls, supplementation of 2-8% PRP-derivative 
significantly increased tube length (p<0.01). Supplementation with higher 
volume% (>15%) of PRP-derivatives showed to decrease tube length 
significantly (p<0.01).
Figure 7. Tube length (pm) o f HUVECs, supplemented with VEGF (20 ng/ml; control) or 
PRP-derivative (various volume%; range 2-20%). Bars represent mean ± SD o f at least 
five samples. ** p<0.01compared to controls.
Number of connections (Figure 8)
Compared to controls, supplementation of 2-8% PRP-derivatives 
significantly increased the number of connections of HUVECs (p<0.01). 
Supplementation of HUVECs with higher amounts showed no significant 
effect on the number of connections (p>0,05)
Figure 8. Total number o f connections form ed by HUVECs, supplemented with VEGF 
(20 ng/ml; control) or PRP-derivative (various volume%; range 2-20%). Bars represent 
mean ± SD o f at least five samples. ** p<0.01compared to controls.
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Discussion
The aim of this study was to evaluate the effects of two standardized 
and significant different groups of PRP from 10 human donors on 
cellular behavior. The standardized PRP's used were 5-fold average 
and 5-fold maximum base line values of platelets in whole blood. These 
standardized PRP's were characterized by determining platelet numbers 
and subsequently growth factor concentrations in the supernatant of 
activated PRP, called PRP-derivatives. Subsequently, both PRP-derivatives 
were used as an additive in cell culture assays using primary osteoblast­
like cells or primary endothelium cells. The results showed significantly 
increased platelet numbers in both PRP's compared to the whole blood 
and also to each other. The growth factors TGF-|31 and PDGF (AA and 
AB) in both groups were significantly increased compared to the whole 
blood, but no difference was seen between the two groups of PRP. In 
other words, the concentrations of growth factors did not increase 
significantly when a higher concentration of platelets was achieved. VEGF 
concentrations were significantly elevated in only the most concentrated 
PRP-derivative. Cell culture experiments with osteoblast-like cells showed 
that both PRP-derivatives stimulated cell proliferation without inducing 
cell differentiation, whereas tube formation in endothelium cell cultures 
was significantly stimulated by adding low volume percentages of PRP- 
derivative (2-8%).
It follows that the hypothesis has to be partially rejected. The increased 
concentration of platelets as compared to the whole blood, had a 
positive effect on the target cells, but there is no significant difference 
in the concentration of growth factors between the experimental groups 
PRPlow and PRPhigh respectively. A platelet concentration of five times the 
maximum base line value has not a more profound effect on the target cells 
than a platelet concentration of five times the average base line value.
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PRP-charac ter iza t ion
The study aimed to evaluate the effects of PRP-derivatives from PRP with 
either 5-fold concentrated average platelet numbers in whole blood (i.e. 
PRPlow) or 5-fold concentrated maximum platelet counts in whole blood 
(i.e. PRPhigh) The results of the platelet count showed statistically significant 
differences between whole blood (mean value 236±98x109 platelets/l), 
PRPlow (mean value 1181 ± 104 x 109platelets/l) and PRPhigh (mean value 1879 
± 125 x 109platelets/l). From the 38 in vitro studies performed on the use 
of PRP in the last eight years, only Ishida et al.29 calculated the occurrence 
of a significant difference between the platelet number in the whole blood 
samples and their experimental PRP . No reference value of the whole blood 
platelet numbers was given in the majority of those studies18,19,22,24,25,30,31,32, 
33,35,36,,38,4o,41,43,44,46,47,52-55. Because of the lack of information and conflicting 
results of the performed experiments on the use of PRP, a standardization 
of PRP-preparation protocols is indicated.
When carrying out studies on the effect of PRP, it is important that the 
variation of the concentration of the platelets in the different PRP groups, is 
minimized. Especially overlap of concentrations between different groups 
of PRP should be avoided when these groups are to be compared. For this 
reason it was the aim of the current study to compare the effect of two 
groups of PRP with significantly different concentrations of platelets.
According to Marx56, in human beings, a sufficient cellular response 
to PRP is expected when a 4-5 fold increase over whole blood platelet 
numbers is achieved. It is, however, not clear whether this concerns 
the individual, the average or the maximum value of the whole blood 
platelet numbers in the peripheral circulation of human beings. For this 
reason, in the present study, its was the purpose to compare PRP of 4 to
5 fold average platelet numbers with PRP of 4 to 5 fold maximum platelet 
numbers, independently of the individual concentration of the platelets 
in the peripheral circulation of the donors. The results show that in these 
two groups of PRP a concentration of 5-fold average platelet numbers 
(PRPlow) and a concentration of 4-fold maximum platelet numbers (PRPhigh) 
were obtained. Unfortunately the volume of the blood samples used was 
not enough to prepare a third group of PRP with a 4 to 5 fold individual 
baseline platelet number. This was due to the fact that the selected donors 
gave blood for clinical use and we were only allowed to use the remnants 
of the prepared platelet concentrates.
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Regarding growth factor concentrations, the results of this study showed 
a statistically significant difference in the concentrations of PDGF-AA, 
PDGF-AB and TGF-|31 between both PRP-derivatives and whole blood. 
Only in the PRP-derivativehigh group, the concentration of VEGF, showed 
a significant difference as compared to whole blood. No significant 
differences were observed between the two PRP-derivatives. It may be 
concluded that platelets are the major source of the released growth 
factors. A large variation in PRP growth factor concentrations has been 
reported by several authors27,32,57,58.
Compared to the current study, Kilian et al.32 reported on similar results 
for TGF-|31 (PRP platelet numbers 1021,9±345,9x109/l), although this was 
not the case for PDGF-AB, -AA and -BB. Han et al.27 showed higher levels 
of PDGF-AB (>100 ng/ml) and TGF-|31 (>400 ng/ml) with PRP platelet 
numbers of 1511x109/l and 1897x109/l, respectively. They reported on a 
dose dependent stimulatory effect of TGF-|31 on cell cultures. PRP with 
50-100 ng/ml TGF-|31 appeared to be an optimal concentration. Han et al.57 
showed much higher levels of PDGF-BB (18000 pg/ml) and TGF-|31 (100000 
pg/ml) in PRP with an eightfold increase over baseline platelet value, 
whilst the level of VEGF (245 pg/ml) was similar to the current study. 
Huang et al.58 reported on higher levels of TGF-|31 (8269,67 pg/ml) and 
PDGF-AB (86449,48 pg/ml) respectively, compared to the current study 
when PRP with platelet numbers 1240x109/l (±159,72) was used.
Roussy et al.42 showed that concentrations of growth factors are time- 
dependent and reported on different concentrations after 0, 1 and 24 hours 
and 6 days. Another influence of growth factor release is the pH of the 
environment. Lui et al.33 demonstrated that a low pH of 5.0 contained the 
highest PDGF concentration, but the lowest TGF-|3 concentration. Other 
factors may be the number of freeze-thaw cycles of PRP and individual 
differences in growth factor release.
In the current study, a statistically significant difference in the number 
of platelets between all three groups was found. The concentration of 
growth factors (TGF-|31, PDGF-AA and AB), however, significant differed 
only between the whole blood and each of the PRP-derivatives, but not 
between the two PRP-derivatives. This implies that there is no direct 
relation between an increase in the number of platelets and a rise in the 
amount of the growth factors released.
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Cel l  c u l tu re  e x p e r im e n t  -  O s te o b la s t - l i ke  cel ls
The present study revealed that both PRP-derivatives had a stimulatory 
effect on the late cell proliferation compared to positive controls. There 
was, however, no significant difference between the PRP-derivatives. 
These results are in contrast with studies that reported on a dose- 
dependent effect of PRP on cell proliferation1,22,25,26,27,29,31,33,35,36,37,40,41,43,44,46,52. 
Six of these studies, however, did not provide detailed information of the 
PRP, which was added to the used cell culture medium25,31,35,41,43,52. Several 
authors describe the use of 1-30% (v/v) PRP in cell culture experiments 
with stimulatory effects on cell proliferation1,29,36,40 . It is of interest that 
Weibrich et al.46 , Choi et al.23, Pietramaggio et al.41 and Hsu et al.28 showed 
significant increases in cell proliferation when adding low volume 
percentages and a decrease in cell proliferation when adding high volume 
percentages of PRP. Weibrich et al.46 and Choi et al.23 showed highest 
increases in cell proliferation at 1-5% PRP addition. Okuda et al.39 showed 
that PRP-addition of 2% and 5% stimulated DNA synthesis in gingival 
fibroblasts, periodontal ligament cells and osteoblastic and osteoblastic 
ligament cells. Similarly, Hsu et al.28 measured a significant increase in 
proliferation of human periodontal ligament cells on 2% and 5% PRP 
gel and a significant decrease on 15% and 30% PRP gel. Considering the 
results mentioned above, it seems that the concentrations used in the 
current study (corresponding to 107x109 platelets/l for PRPlow and 159x109 
platelets/l for PRPhigh) were relatively high. Nevertheless, the observed 
stimulation of cell proliferation was clear and similar for both PRP- 
derivatives.
Results of the ALP activity analysis, a marker for early differentiation of 
osteoblast-like cells, showed the inability of PRP-derivatives to induce 
osteoblast-like cell differentiation. These results are in keeping with 
the findings of Arpormaeklong et al.21, Kanno et al.1, Ogino et al.36, van 
den Dolder et al.45 and Zaky et al.47, which all reported on a significant 
suppression of early differentiation by PRP. Some studies, however, 
reported on an early increase of ALP-activity of periodontal ligament 
cells, osteoblasts or adipose derived stroma cells respectively, when using
PRP20,27,31,34,44.
The lack of early osteoblast-like cell differentiation as found in the current 
study, is related to the absence of mineralized matrix deposition within 
the extracellular matrix during cell culture. The calcium content of PRP- 
derivative supplemented cultures was found to be permanently low, 
whereas positive controls (i.e. cultures in osteogenic medium) showed a
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profound increase in the latest stage of the culture. The measurements 
of ALP-activity and calcium content were supported by the presence of 
mineralized nodules in positive controls, whereas these nodules were 
absent in PRP-derivative supplemented cultures. In contrast, some studies 
reported on stimulation of early and late differentiation30,31,32,44. Liu et al.34 
demonstrated also induction of early and late differentiation by PRP, 
whilst no osteogenic medium was added to the experimental PRP groups. 
Van den Dolder et al.45 showed even a significant positive effect of PRP on 
the late differentiation of osteoblast-like cells (i.e. significant increase in 
calcium deposition after 8, 12 and 16 days), in spite of a negative effect of 
PRP on the ALP activity at day 4, 8, and 12. The addition of PRP in their 
set-up, however, was different from the one in the present study (PRP- 
coating vs. PRP-derivative addition to cell culture medium), the exact 
reason for this discrepancy remains unclear.
Cel l  c u l tu re  e x p e r im e n t  -  Endo the l iu m  cel ls
Since there is hardly any information on the use of tube formation assays 
to analyse the potential pro-angiogenic effects of PRP, a commercially- 
available method for screening angiogenesis59 was used. In the current 
study, this method was used with VEGF-stimulation (20 ng/ml) as a positive 
control next to both PRP-derivatives in different volume percentages.
The results of the tube formation analysis showed significant effects on 
tube length and number of connections for 2%, 5% and 8% supplementation 
of either PRP-derivative compared to positive controls. The optimal 
volume percentage of PRP-derivative was found to be approximately 5% 
for each PRP-derivative. The actual concentrations of growth factors in 
the cell medium of 5% for PRP. or PRP, , corresponded with plateletslow high
numbers of ~60x109/l and ~90x109/l, respectively (Table 2). Weibrich 
et al.46 and Choi et al.23 showed highest increase in cell proliferation at 
58,9x109 platelets/l and 12 to 62x109 platelets/l (1-5%), respectively. In both 
studies, however, different cells i.e. osteoblast-like cells and alveolar bone 
cells were used, but no endothelium cells. To date, only two studies used 
PRP in combination with endothelium cell culture (human umbilical vein 
endothelium cells; HUVECs)60,61. Frechette et al.60 reported on a strong 
beneficial effect of PRP on the proliferation of human osteoblasts and 
endothelium (HUVEC) cells. The authors found that supernatants, which 
were formed after activation of PRP by adding calcium chloride and 
thrombin, appear to be more mitogenic for HUVEC's than non-activated 
PRP supernatants. In contrast, PRP activation had little additional benefit
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on osteoblast proliferation. The amount of calcium chloride and thrombin 
added, revealed to be of influence on the proliferation, but the authors 
concluded that additional experiments are needed to determine which 
concentrations are optimal for bone formation in vivo.
Based on the results from in vitro vasculogenesis of endothelium cells, 
Hofmann et al.61 created a long-term co-culture model of HUVECs and 
primary human osteoblasts employing polyurethane and PRP in a static 
micro environment. The authors concluded that growth factors released 
from PRP are likely to provide additional stimulation for growth and 
maturation of HUVECs. The results of the current study are in accordance 
with this conclusion, since both PRP-derivatives showed improved tube 
formation compared to VEGF alone, even within 16-18 hours.
Conclusion
The results of this study reveal that there is no direct relationship between 
the number of platelets and the level of growth factors released from these 
platelets. Proliferation of the osteoblast-like cells was stimulated only in 
a late phase by both PRP-derivatives. Both early and late differentiation 
were suppressed by PRP. Early angiogenesis was significantly increased 
by a relative low concentration of PRP. This appeared to be the optimum 
concentration since higher concentrations decreased angiogenesis. From 
the cell culture and tube formation assays, one may concluded that a 
relatively low concentration of activated platelets may stimulate the 
proliferation of target cells, but slightly higher concentrations have already 
an inhibitory effect. Although these platelet numbers are far beneath the 
physiological level in the peripheral blood of human beings, it may be 
that forced ex vivo activated platelet-rich plasma produce more growth 
factors as compared to human whole blood, activated under physiological 
conditions. This study also confirmed that PRP in a concentration of five 
times the average value has an effect on the proliferation of osteoblasts.
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reconstruction of the m andible: prp, titanium plates, cortica l and cancellous bone
Introduction
Reconstruction of the mandible after ablative surgery for benign or 
malignant tumours still poses a challenge to the oral and maxillofacial 
surgeon. Microvascular composite free flaps, however, have gained 
enormous popularity particularly in cases of malignant tumours1,2,3'4'5. 
These grafts are highly reliable in terms of survival and, therefore, serve 
their purpose well with regard to providing continuity of the jaw. An 
additional advantage of these grafts is the possibility to add healthy 
soft tissues to the defect, which is of significant benefit when radiation 
therapy is involved and when the resection also includes large parts of 
the mouth or adjacent soft tissues6,7,8,9. A drawback of these grafts is the 
limited bone volume, especially when the resection involves a dentate part 
of the mandible. Height and width of the transplanted bone may not be 
sufficient to place implants in the desired locations to fabricate an optimal 
prosthetic device10,11,1213. There also is donor site morbidity and investment 
of time and resources of the surgical team. The latter is particularly the 
case in developing countries.
There are also cases where microsurgery is not needed, because there is 
no lack of soft tissues whereas the defect is limited to the bone. The latter is 
often the case when dealing with aggressive odontogenic tumours. There 
are also situations where bony defects occur because of other reasons 
like, osteoradionecrosis, broken reconstruction plates, osteomyelitis, or 
iatrogenic defects as a result of poorly managed implant surgery.
Free bone grafts, be it block grafts or compressed particulate marrow 
grafts, have also been successfully used in selected cases. There are, 
however, limitations to the size of these grafts and block grafts tend to be 
susceptible to infection, particularly when used for primary reconstruction 
after ablative surgery when a communication exists between the oral 
cavity and the skin. Free bone grafts, however, do have the advantage 
that they usually provide enough volume to insert implants in the most 
strategic location. For this reason they may still be useful for secondary
reconstructions6,14,15,16.
Particulate autogenous bone grafts compressed in trays are another option. 
This method was widely used in the sixties and seventies and underwent 
refinement by using custom made trays17,18,19. One method to improve on 
the use of compressed particulate bone grafts has been introduced by 
Marx et al. in 199820. Before that Tayaponsak et al.21 had already added 
autogenous fibrin adhesive to the cancellous bone graft and reported on
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the early radiographic healing in 33 patients who underwent mandibular 
reconstruction. Whitman et al.22 reported on the use of autogenous platelet 
gel in various applications, among which was the successful reconstruction 
of mandibles. Marx et al.20, however, reported on a study of 44 cases of 
secondary reconstructions using 4 to 5 times concentrated autogenous 
platelet-rich plasma (PRP), added to the particulate cancellous bone graft. 
They claimed enhanced bone healing when comparing the results with 44 
cases in which he did not use PRP. Since then, several authors23,24,25 have 
reported on successful reconstructions using PRP. Merkx et al.23 reported 
on 8 patients who underwent a secondary reconstruction of the mandible 
after a segmental resection because of a malignancy. All patients healed 
uneventfully. In 6 patients a biopsy showed bone remodelling, in one 
patient abundant fibrous tissue was seen. The concentrations of PRP 
varied, with a mean of 9657x109/l. Thorn et al.25 reported on 10 patients who 
underwent reconstruction in the maxillofacial region, eight mandibular 
reconstructions, of which seven with osteoradionecrosis and one after 
resection because of an ameloblastoma and two augmentations of the 
maxilla. All of these patients healed uneventfully. In this study a fibrin 
glue, fibrin and PRP, was used, but no information, however, was given 
about the concentration of the platelets in the PRP used. In contrast to 
the other studies mentioned23,24, a high concentration of fibrin was added 
to the PRP. The authors stated that the concentration of growth factors 
(platelet-derived growth factor, PDGF) was approximately eight times the 
value in platelet-rich plasma and reported on a fibrinogen concentration 
of approximately 12 times the value in platelet-rich plasma. Simon et al.24 
presented 11 patients with an ameloblastoma who underwent ablative 
surgery followed by reconstruction of the mandible in a single procedure. 
Four of these patients had some complications which were probably 
related to the use of an irradiated autogenous scaffold. The concentration 
of platelets in the PRP used varied from 1000-2000 x109/l.
In all three above mentioned clinical human studies, particulate 
cancellous bone from the iliac crest was used as a graft and the great 
majority of the reconstructions concerned the mandible. There was, 
however, a great variety of the trombocyte concentrations in the PRP's 
used. Since the survival rate of the grafts was high, no conclusions can be 
drawn about a relation between the concentration of the PRP used and 
the variability of graft success.
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Since the introduction of PRP numerous animal studies have been 
conducted to investigate its working mechanism. The results of these 
investigations have been rather confusing in that variable results were 
obtained, ranging from positive to negative. Some of the studies conducted 
at our institution also revealed conflicting results26,27,28. The possible 
reasons for these less desirable results are discussed in a separate article27. 
In summary, the surgical site may influence the results. For example, in 
contrast to periosteum and dura29, respiratory epithelium (sinus floor 
elevation) can act as a resorptive endosteum30. The kind of bone used may 
also play a role, since particulate cortical bone proved not to heal in a 
predictable fashion31. The main reason, however, may be that the average 
concentrations of blood platelets used in the various studies did not take 
into account the great variation in the baseline values of the animals and, 
thus, the variation in the concentration of the platelets in the PRP used. 
It can also not be ruled out that there is a difference in the concentration 
of platelets needed for acceleration of bone formation between different 
animal species or even between individuals of one species.
Despite these rather negative results in some animal studies, we have 
continued to use PRP in a clinical setting, because the results seen were 
not giving rise to any doubts about the efficacy of the method used in 
reconstructing human mandibles.
The aim of this retrospective study is to present the results of a series 
of selected patients in whom our technique was used, including a stable 
means of fixation and the addition of PRP to the particulate autogenous 
cancellous bone graft, to reconstruct lost parts of the mandible.
Material and Methods.
Twenty selected but consecutive patients, who needed reconstruction of 
the mandible were included in this study. Eighteen were treated at the 
department of Oral and Maxillofacial Surgery of the Radboud University 
Medical Centre Nijmegen and two at the Department of Cranio- 
Maxillofacial Surgery of the Maastricht University Medical Centre .
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Criteria for inclusion were:
• All patients who underwent a segmental resection of the mandible 
for a squamous cell carcinoma in the period 2000-2008 and who 
did not undergo primary reconstruction (group 1, n=10).
• All patients with a benign, but aggressive odontogenic tumour, 
in the period 2000-2008, who underwent a segmental resection of 
the mandible and in whom primary reconstruction was planned 
(group 2, n=7)
• All patients with severe alveolar resorption and non-healing 
fractures of the mandible in the period 2000-2008 (group 3, n=3).
All patients were given extensive information about the procedure 
and consented to the type of reconstruction. Four of the 10 secondarily 
reconstructed patients (group 1) had also undergone radiotherapy 
amounting to about 60 Gy. On eight of these secondary reconstructed 
patients Merckx et al.23 had reported on earlier. PRP in this group of 
patients was prepared as described in that article. In the remaining 12 
patients, homogenous PRP was used, prepared by the blood bank (Sanquin, 
Nijmegen, The Netherlands). The concentration of the platelets in the 
PRP prepared, varied from 1466 x 109/l to 9272 x 109/l (mean 5400 x 109/l, 
SD 2084).
The autogenous bone was harvested from either the anterior or posterior 
iliac crest depending on the amount of bone needed. The posterior iliac 
crest was used in all primary reconstruction cases and in all, except for one 
of the patients who needed secondary reconstruction. In all cases a cortico- 
cancellous graft was harvested with a length that would approximately 
match the size of the defect. When that was not possible the largest 
possible graft was taken, which would measure approximately 10 by 5 cm. 
In addition, an adequate amount of cancellous bone was harvested. In 
cases of posterior iliac bone harvesting the patients had to be turned on 
their back before reconstruction of the mandible was possible
In all cases of primary reconstruction segmental mandibular continuity 
resections of 8 to 12 cm in length had been carried out through a 
submandibular and intra-oral incision. For secondary reconstruction 
submandibular incisions in the preexisting scars were used. In this 
group the size of the defects varied also from 8 to 12 cm. In the three 
cases of malunion after fractures, in whom implant surgery had failed, 
low submandibular incisions were used to expose the bone stumps of 
the mandible. In all of these cases unsuccessful attempts had been made
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nr. g e n d e r a g e histo lo gy m a lig n . b e n ig n e other lo ca tio n sta g e prim ary  th e ra p y  
RT C T  surg.
HBO p o st-op  
RT CT
ORN
1 m 59 scc 1 tongue T4N2cM0 60 Gy 1 1 1
2 f 62 scc 1 oropharynx T2N0M0 78 Gy 1 1
3 f 75 scc 1 trig. retrom. T4N0M0 1 1
4 m 50 scc 1 trig. retrom. pT4NoMo 1 60 Gy 1
5 f 41 scc 1 oropharynx pT2NoMo 1
6 f 41 scc 1 floor of the mouth T4N0M0 1
7 m 65 scc 1 mandible T4N0M0 1
8 m 59 osteosarcoma 1 mandible 1 1 1
9 m 46 m align. fibr. histioc. 1 mandible T4 1
10 f 54 scc 1 trig. retrom. pT4N2bMo 1 1 60 Gy
11 m 35 amelobastoma 1 mandible 1
12 m 61 ameloblastoma 1 mandible 1
13 f 27 ameloblastoma 1 mandible 1
14 m 13 ameloblastoma 1 mandible 1
15 f 44 calcifying odontogenic fibroma 1 mandible 1
16 f 56 odontogenic myxoma 1 mandible 1
17 m 13 cemento-oss fibr. 1 mandible 1
18 m 50 pseudo-arthrosis 1 mandible 1
19 m 62 pseudo-arthrosis 1 madible 1
20 f 55 pseudo-arthrosis 1 mandible 1
48 10 7 3 2 1 18 3 2 1 5
Table 1. The particulars o f the three groups o f patients who underwent reconstructive 
surgery. s.c.c.: squamous cell carcinoma, RT: radiotherapy, CT: chemotherapy, HBO: 
hyper baric oxygen therapy, ORN:osteoradio necrosis.
earlier to stabilize the fractures with osteosynthesis plates. These defects 
varied in size from 2 to 4 cm in size. The particulars of the three groups of 
patients, who underwent reconstruction, are presented in Table 1.
The reconstructive procedure in all secondary cases included adequate 
exposure of the defect site. The bony stumps were exposed on both the 
lingual and buccal side. The occlusion was temporarily fixed by applying 
arch bars and intermaxillary fixation in the dentate patients, to achieve 
the proper size of the defect. In the edentulous cases the size of the defect 
was estimated by bringing the symphysis in the midline. This was also 
applied for the three patients with extremely resorbed mandibles and 
malunions. In the patients with the aggressive odontogenic tumours the 
size of the defect could easily be calculated from the resected specimen. 
These patients were also temporarily fixed in the proper occlusion.
In all but the three cases from group three, two 2,3 mm pre-shaped 
titanium plates (Martin KLS, Smart plates®) were used to stabilize the 
fragments in the desired position. In the three other cases only one 
straight 2,3 mm bridging plate was applied, since there was no room for 
a second plate.
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Fig.1 Schematic lateral view o f the reconstructed area o f the mandible before the 
mixture o f autogenous particulate cancellous bone and activated PRP had been applied. 
The medially placed cortical bone plate is fixed to the muscles and soft tissues o f the floor 
o f the mouth, using mattress sutures. The titanium plates are on the lateral side o f the 
mandible.
Fig.2 Panoramic view o f the reconstructed left mandible. In this case radio-opaque 
tricalcium phosphate grains were added to the mixture o f autogenous particulate 
cancellous bone and activated PRP.
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At this stage attention was directed towards the harvested bone graft. First 
the cancellous bone was removed from the cortex. Then the cortical plates 
were cut to fit the defect both in height and length. When the size of the 
defect exceeded the length of the cortex an additional piece of cortex had 
to be used . The cortical bone specimen were then fixed to the muscles 
and soft tissues of the floor of the mouth, using mattress sutures (Vicryl 
3-0, Ethicon, Johnson&Johnson) (Fig. 1). In this way the particulate graft 
material to be applied would not spill into the floor of the mouth.
The particulate grafts were then prepared and mixed with the PRP that 
was activated by CaCl2 and thrombin, for which Tissucol® was used. In 
two patients in group 2 tricalcium phosphate grains were added to expand 
the graft and make it detectable on the radiographs (Fig. 2). After mixing 
the graft with the activated PRP, a malleable substance was created which 
facilitated its application in the defect region. The graft was applied between 
the cortical plate and the titanium plates (Fig. 3). Special attention was paid 
to compress the graft as much as possible as well as to insert as much viable 
bone cells as possible. Because the cortical plates were fixed to the floor of 
the mouth, the gap between the cortex and the titanium plates tended to 
widen when the particulate grafts were compressed against the cortical 
plate(s). This allowed for adapting of the width of the graft to the needs, 
particularly when implants were planned for a prosthetic reconstruction.
Fig.3 Schematic cranial view o f the reconstructed area o f the mandible after the mixture 
o f particulate cancellous bone and activated PRP had been applied between the cortical 
plate and the titanium plates.
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In this way, the full height and width of the original mandible could be 
restored. Meticulous intra-oral two-layer suturing (Vicryl rapide 3-0, 
Ethicon, Johnson&Johnson) was performed when necessary. The extra­
oral wounds were closed in three layers; the subcutus with Vicryl 3-0 and 
the skin with Ethilon 4-0, Ethicon, Johnson&Johnson. We administered 
1000 mg cephalexine and 500 mg metronidazol intravenously one hour 
before surgery and three hours after the beginning of the operation.
One or two day's post operatively a panoramic radiograph was made 
and mobilisation of the patients was started as soon as possible. In the 
dentate cases intermaxillary fixation with steel wires had been replaced 
after one week by elastics. All the patients were advised to follow a soft 
diet for six weeks. The mean stay in the ward was seven days (range 3-9 
days). Implantation, when indicated, was planned about six months after 
reconstruction.
All patients were seen for regular follow-up. At the last follow-up they were 
specifically asked about their opinion regarding the reconstruction. Patients 
were asked to asses the results as good, satisfactory, sufficient, or poor.
Results
The follow-up time ranged from 1 to 8 years. All patients took part in the 
follow up except for one who was admitted to a nursing home.
Initial healing in all but three patients, two from group 1 and 1 from 
group 2, was uneventful. These three patients had wound dehiscence 
resulting in partial bone loss. Two of these patients, both from group 1, 
had previous radiotherapy. Conservative measures such as antimicrobial 
treatment, rinsing and improvement of oral hygiene resulted in secondary 
healing in all three patients, although in one patient from group 1, an 
additional hyperbaric oxygen therapy was carried out to support local 
wound healing. The follow-up differed in the three patient groups and, 
therefore, is reported separately.
G roup 1: In nine of 10 patients no further complications had occurred. 
In four patients seven implants were inserted in the grafted bone, 
approximately 6 months after reconstruction. In one patient an abscess 
developed approximately 7 months after reconstruction. On exploration, 
it appeared that anteriorly of the reconstructed part of the mandible, 
a fracture had occurred due to resorption because of peri-implantitis 
around one of three implants that were in place before the reconstruction
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was carried out. After consolidation another reconstructive attempt was 
undertaken with an autogenous bone graft taken from the anterior iliac 
crest, which was also mixed with PRP. Fixation was achieved in the fashion 
as described before. This reconstruction also turned out to be successful. 
At the time of the last control the contour of the mandible was found 
to be good in five patients and satisfactory in four by both the patients 
and clinicians. One patient was lost to follow-up because of the reason 
mentioned before.
G roup 2 : In two of the seven patients a localized abscess occurred, at 2 and
7 months after reconstruction. This appeared to be related to sequesters 
that were subsequently expelled. Both patients had to be operated again 
and additional bone grafts were placed to assure that implants could be 
inserted in the optimal positions. In five patients a total of 14 implants 
were inserted in the reconstructed area. At the time of implant insertion, 
granulation tissue instead of solid bone was found in some regions of 
the reconstructed bone segments. For this reason, however, in only one 
of these five patients, it was necessary to carry out an additional local 
augmentation before implant placement (Fig. 4).
Fig.4 Onlay graft in the premolar region after reconstruction o f the 
right mandible in order to improve the local situation before implant 
placement.
There was no case of bony malunion at the transit regions between the 
stumps and the new bone. The contour of the mandible was considered 
to be good in 4 and satisfactory in 3 cases by both the patients and the 
clinicians. The less satisfactory results were reported because of slight 
asymmetries in the lower border of the mandible (Fig. 5).
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Fig.5 Resorption o f the lower border o f the mandible causes slight 
asymmetry in some cases.
Fig.6 In two patients o f group three, additional augmentation o f the 
anterior (non reconstructed part) mandible was necessary before implants 
could be placed.
Fig. 7 Resorption on the lower border o f the graft. The "dent" has been 
corrected with a lyophilised cartilage graft fixed with wires.
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G roup 3 : Primary wound healing was achieved in all three patients. Two 
patients had to undergo additional surgery to augment the mandible 
in the symphysis area, outside the area that was grafted before (Fig. 6). 
This was done to allow for implant placement and the fabrication of an 
overdenture. However, no implants were placed directly in the region of 
interest. The contour of the mandible was considered to be good in one 
and satisfactory in two cases.
Despite the attention paid to achieve a sufficient bone height in the primary 
reconstructive attempt, in several patients resorption had occurred at both 
the inferior and superior border. In one case correction of a resorption 
defect was indicated (Fig. 7). In eight patients 19 implants had been 
successfully placed in the reconstructed area. In some cases the shape of 
the reconstructed mandible was almost anatomic (Fig. 8).
Fig. 8 Intra-operative view 
after 3 implants have been 
inserted in the reconstructed 
mandible which has an almost 
anatomical shape.
Discussion.
Continuity of the mandible was achieved in all cases. This is in accordance 
with the results reported by Marx et al.20, Merkx et al.23, Thorn et al.25, 
and Simon 200624. Pogrel et al.7 considered failure as loss of all or part of 
the graft resulting in a residual continuity defect requiring further bone 
grafting. They concluded that the failure rate of non vascularized bone 
grafts, in which no PRP was used, was 17% when the defect was 6 cm 
or shorter, increasing to 75% for grafts over 12 cm in length. The present 
study, however, does not include controls, because the size of the defects 
was such that it was not considered ethical to subject patients to grafting 
without PRP and thus running a high risk of failure. In the present study, 
four out of 20 patients needed additional vertical bone grafting to improve 
the bony situation before implant placement, although no residual
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continuity defect had occurred. Considering the size (8-12 cm) of seventeen 
of the defects in the present study, the results may be considered rather 
satisfactory. The antimicrobial effect of both autogenous and homogenous 
PRP, which may be dose dependent32, is probably accountable for the low 
infection rate32,33,34,35.
The use of cortical struts, which were positioned on the lingual side of the 
defect and sutured to the muscles of the floor of the mouth, served their 
purpose well. It prevented the particulate graft from migrating into the floor 
of the mouth and allowed for reasonable condensation of the particles. It did 
not contribute to the rigidity of the stumps because the 2,3 mm plates on the 
buccal side provided excellent stability.
The initial healing problems that occurred in three patients are probably 
related to the previous radiotherapy in two cases, whereas one patient had 
a rather long history of disturbed wound healing after several attempts of 
bony reconstruction.
It appeared that in some cases the graft was partially replaced by granulation 
tissue, which probably reflects the working mechanism of transforming 
growth factor |3 (TGF-|3).This growth factor not only promotes the proliferation 
of osteoblasts and osteoclasts but also of fibroblasts. It appears that in certain 
circumstances fibroblastic proliferation prevails over the osteoblastic activity. 
This may be due to a bifasic effect of TGF-|3 on bone cell proliferation; at 
relatively low concentrations, it stimulates bone cell proliferation, whereas at 
higher doses, proliferation is suppressed36.
Fibroblast proliferation due to exposure to a platelet concentrate has also been 
reported to be pH dependent in an in vitro study37. The authors concluded that 
an acid environment (pH 5,0) results in activation and/or release of platelet- 
derived growth factor (PDGF) from alpha granules of activated platelets 
with resulting fibroblast proliferation. The secretion of TGF-|3 however, was 
enhanced by a higher, rather than a lower, pH. The pH of the wound and 
its surroundings shifts from acidic through neutral to alkaline conditions 
as wound healing progresses, which may explain the enhanced fibroblast 
proliferation during the early wound healing, particularly in compromised 
conditions, such as pre- and postoperative radiotherapy.
The use of homogenous PRP was suggested by the blood bank. The safety 
precautions in the Dutch regulations for the preparation of blood products 
are such that this was thought to be acceptable since the same precautions 
apply for persons who receive homogenous platelets for other reasons. The
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potential donors were screened for: HBV, HCV, HIV 1 and 2 , HTLV 1 and
2 and Treponema Pallidum. One also has to realize that in the preparation 
of platelet concentrations erythrocytes and leucocytes are separated from 
the platelets by cytaferesis. The chances of undesirable antigenic effects 
or contraction of diseases like HIV are, therefore, excluded. On the other 
hand, the availability of PRP on the shelve facilitates its application, and the 
patient does not have to donate his or her own blood. Each patient, however, 
was given the opportunity to chose either autogenously or homogeneously 
prepared PRP.
The concentration of platelets in the PRP prepared, varied from 1466x109/l 
to 9272x109/l (mean 5400x109/l, SD 2084). The baseline value of the 
concentration of platelets of human blood varies from 120-350 x 109/l (mean 
235x109/l). This means a 23 fold (minimum 6, maximum 39) increase over the 
baseline platelet numbers. According to Marx38, a sufficient cellular response 
to platelet concentrations in human beings begins when a 4 to 5 fold increase 
over baseline platelets numbers is achieved. It was assumed at the start of this 
study that higher concentrations of PRP would be more effective. On the basis 
of this information, in this study, the blood bank tried to achieve a platelet 
concentration as high as possible. Later, because in some cases granulation 
tissue was found in some areas at the time of implant insertion, it was thought 
that these high concentrations of PRP may have been counterproductive. For 
this reason, the concentration of the PRP used was lowered to a level of 4 to 5 
times the mean value of baseline platelet numbers38 in the last two cases: one 
in group 1 and one in group 2. The initial attempt to achieve a concentration 
of platelets as high as possible, however, resulted in a great variety in the 
concentration of platelets in the PRP's (3300x109/l to 9272x109/l). This was 
because of the variety of the individual values of baseline platelet numbers.
Weibrich et al.39 reported on the in vitro effect of PRP on the proliferation 
rate of human osteoblasts. The osteoblasts were stimulated by different 
dilutions of PRP. They found that the effect of PRP on the proliferation of 
human osteoblasts is concentration dependent until a certain plateau is 
reached. Further stimulation (i.e. a higher concentration of thrombocytes) led 
to a slight decrease in the proliferation rate. Weibrich et al.40 also reported on 
the effect of the platelet count in platelet-rich plasma on bone regeneration 
in rabbits. They concluded that the platelet concentration required for a 
positive PRP effect on bone regeneration seems to span a very limited range. 
Advantageous biological effects seemed to occur when PRP with a platelet 
concentration of approximately 1.000.000/microl was used. These findings 
are in keeping with the results of a recently performed in vitro experiment41.
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By use of increasing dilutions of PRP and human umbilical vein endothelial 
cells, early angiogenesis was significantly increased by a relative low 
concentration of PRP. This appeared to be the optimal concentration because 
higher concentrations decreased angiogenesis. At lower concentrations, 
however, the effect was sub optimal. In retrospect, the high concentrations 
used in our study may have been counterproductive in that they probably do 
not represent the optimal concentration to stimulate osteoblast proliferation.
In this context, the results of a study by Graziani et al.42 are of interest. They 
performed an in vitro study on human osteoblasts and fibroblasts function. 
They found optimal results when a 2,5 fold platelet concentration was 
used. Kalen et al.43, found a considerable variation in the content of bone 
morphogenetic proteins (BMP's) in platelets from different human donors. 
The authors suggested that this variation may be of importance considering 
the ambiguous results previously reported on osteoblast proliferation and 
differentiation. In an in vitro study by Tomoyasu et al.44, 3-dimensional 
scaffolds of collagen sponges or hydroxyapatite were pre-treated with a 
mixture of BMP-4 and increasing amounts of soluble PRP. Mesenchymal 
progenitor mouse cells were cultured on these pre-treated scaffolds. The 
authors found dual effects of the PRP used on proliferation and differentiation. 
At lower concentrations, the PRP fraction markedly stimulated the osteoblastic 
differentiation in the presence of BMP's, whereas at higher concentrations, 
the same fraction stimulated proliferation and suppressed osteoblastic 
differentiation. They suggested, therefore, that optimal dosages of PRP and 
BMP's must be determined to stimulate bone formation in vivo.
A serious drawback of our study is it's retrospective nature, and the group 
of patients is also somewhat heterogeneous. Over the years, however, no 
modifications of the technique used have been implemented. Despite the lack 
of controls and the relatively small group of patients, this study supports the 
notion that PRP has an advantageous effect on bone graft healing. No surgeon 
would presently contemplate bridging gaps of more then 5 cm with free bone 
grafts. The fact that all gaps in this study were far larger than 5 cm and in all 
cases continuity was achieved attests to the validity of the method reported. 
The antimicrobial effect as well as the proliferation of the osteoblasts are 
likely to be responsible for the results achieved. The concentration of PRP 
used was probably too high, given the results of the recent in vitro study 
on human osteoblast and endothelium cells41. To substantiate the previous 
claim, a prospective study should be carried out, but it is unlikely that at 
present, ethical committees would allow for a control group not using PRP, 
considering the size of the defects treated.
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In reconstructive surgery of the facial skeleton, both vascularized and non-vascularized graft techniques are used. Vascularized graft surgery is the gold standard in reconstructive surgery because these 
grafts are highly reliable in terms of survival, especially when post­
operative radiotherapy is indicated. A drawback of these grafts is the 
limited bone volume and lack of possibilities to restore the precise three­
dimensional shape, especially when the resection involves a dentate part 
of the mandible. The harvest of bone grafts also always causes substantial 
donor site morbidity. Tissue engineering may have the potential to 
improve on the aesthetical and functional results of skeletal reconstruction 
and also may avoid or substantially reduce donor site morbidity. Tissue 
engineering requires a matrix, (precursor) cells and growth factors. Yet, in 
reconstructive surgery of the bony skeleton of the face, tissue engineering 
techniques are far from being applicable as a standard procedure.
Platelets contain many growth factors, which have been shown to be 
involved in wound healing and in processes that culminate in parenchymal 
cell proliferation and tissue regeneration. Autogenous or homogenous 
platelet concentrates are cheap and easily to prepare by blood bank 
procedures or desktop devices (only autogenous). For these reasons the use 
of platelet-rich plasma (PRP) in bony reconstructive surgery of the facial 
skeleton, is promising. At the time this study started, scientific evidence 
to support the beneficial effect of the addition of PRP to autogenous 
bone grafts or alloplastic bone substitutes was lacking. In the past eight 
years many animal and several human studies on the use of PRP in bony 
reconstruction revealed contradictory results. There is, therefore, still no 
conclusive evidence on the working mechanism and beneficial effect of 
PRP on bone healing. The studies in this thesis attempted to clarify the 
effects of PRP on bone healing in more detail.
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C h ap ter 1 presents a description of the relevant content (vesicles/granules) 
of platelets. The function of the several important growth factors in wound 
healing, stored in the a-granules of platelets, is emphasized. The way 
platelets and, thus, PRP gets activated and releases its growth factors, is 
described. After a synopsis of the history of PRP, a resume is given on the 
use of PRP in animal experimental and in vitro studies. Some possible 
explanations for the conflicting results of these studies are given. Based 
on the results of the first systematic review on the use of PRP in human 
skeletal reconstruction, the substantial heterogeneity of the human studies 
done is emphasized.
Aims:
1. To investigate the early and late effects of PRP on bone healing.
C h ap ter 2 reports on an experiment in twenty goats. In the forehead 
of each goat four round critical size defects were made. In all goats the 
defects were filled with a standardized amount of autogenous particulate 
cancellous bone, in which one millilitre of platelet-rich plasma (PRP) was 
added in two of the four defects. All goats had an uneventful healing. 
This group of twenty goats was divided in four subgroups of five goats 
each, which were sacrificed after 1, 2, 6 and 12 weeks. The results of the 
histological and histomorphometric examination showed, that the early 
and late bone healing was not enhanced, when PRP was used.
2. To investigate the early and late effects of PRP on bone healing of a
mixture of autogenous bone and a bone substitute
In C h ap ter 3 also an experimental study in twenty goats, using the same goat 
model, is presented. To reduce the amount of autogenous bone, however, a 
bone substitute was added. The hypothesis was that PRP would accelerate 
bone healing of a mixture of autogenous bone and an osteoconductive 
alloplastic material. The purpose of this experiment was to study the 
effect of PRP on a mixture of autogenous bone and deproteinized bovine 
bone mineral (Bio-Oss®) particles in goats. Four round critical size defects 
were made in the forehead of each goat. In all goats the defects were filled 
with a standardized mixture of autogenous particulate cancellous bone 
and (Bio-Oss®) particles, in which one millilitre of platelet-rich plasma 
(PRP) was added in two of the four defects. All goats had an uneventful 
healing. This group of twenty goats was divided in four subgroups of five
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goats each, which were sacrificed after 1, 2, 6 and 12 weeks. The results 
of the histological and histomorphometric examination showed that the 
early and late bone healing was not enhanced when PRP was used.
3. To quantify the growth factors of PRP in 3 different species and to
study the effect on rat bone marrow cells.
C h ap ter 4  reports on an in vitro study evaluating the levels of several 
growth factors in PRP's of three different species and the effect on growth 
and differentiation of rat bone marrow cells. The concentrations of TGF- 
b1, PDGF-AA, PDGF-AB, and PDGF-BB in rat, goat, and human PRP 
were determined. Overall, the immunoassays revealed that human PRP 
contained higher concentrations of growth factors per platelet compared 
to rat and goat PRP. Goat PRP showed higher concentrations of growth 
factors per platelet as compared to rat PRP except for PDGF-BB, which 
had a higher concentration in rat PRP. TGF-b1 was the most abundant 
growth factor in all 3 PRP's.
Rat bone marrow cells were cultured in PRP-coated wells or in uncoated 
wells for 16 days in osteogenic medium, and analysed on cell growth 
(DNA content) and cell differentiation (alkaline phosphatase [ALP] 
activity, calcium content, scanning electron microscopy, and QPCR). 
The results showed that PRP stimulated initial cell growth and had no 
effect on ALP activity. The real-time PCR results showed that PRP up 
regulated osteocalcin at day 1 and collagen type I at day 8. The calcium 
measurements showed a significant increase in calcium at days 8, 12, and
16. The results of this in vitro study indicate a difference in growth factors 
levels of PRP (per platelet) from different species. This study reveals 
that rat PRP gel stimulates initial growth and differentiation of rat bone 
marrow cells in vitro.
4. To quantify the concentration of several growth factors within two
different concentrations of human PRP.
5. To study the effect of these different concentrations of PRP on rat
osteoblast-like cells.
6. To define the optimal concentration of PRP to stimulate early 
angiogenesis.
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In C h ap ter 5 an in vitro study is presented, evaluating the effects of 
standardized PRP's from 10 human donors on cellular behavior. The 
standardized PRP's used were 5-fold average and 5-fold maximum base 
line values in whole blood. These standardized PRP's were characterized 
by determining platelet numbers and subsequently growth factor 
concentrations in activated PRP's (PRP-derivatives). Subsequently, both 
PRP-derivatives were used as an additive in cell culture experiments 
using primary rat osteoblast-like cells or primary human endothelium 
cells. The results showed significantly increased platelet numbers in both 
PRP's, compared to whole blood and to each other. Both PRP-derivatives 
contained significantly higher concentrations of PDGF-AA, PDGF- 
AB and TGF-|31 compared to whole blood but not to each other. VEGF 
concentrations were significantly elevated in only the most concentrated 
PRP-derivative. Cell culture experiments with osteoblast-like cells showed 
that both PRP-derivatives stimulated cell proliferation without inducing 
cell differentiation, whereas tube formation in endothelium cell cultures 
was significantly increased by adding low volume percentages of both 
PRP-derivatives (2-8%). Consequently, it can be concluded that there is 
no direct relationship between the number of platelets and the level of 
growth factors released from these platelets. PRP-derivatives have the 
potency to stimulate angiogenesis dose-dependently, while lacking the 
capacity to induce osteogenic differentiation. The proliferation, however, 
of osteoblast-like cells can significantly be enhanced by the addition of 
PRP-derivatives.
7. To evaluate the effect of PRP for the reconstruction of large mandibular 
defects in human beings
C h ap ter 6 describes the clinical application of PRP. In twenty patients 
pre-shaped 2.3 mm titanium plates, autogenous cortical bone plates, 
particulate cancellous bone grafts and platelet-rich plasma were used 
to bridge mandibular defects of 8-12 cm.. The results are presented on 
three groups of patients. Group 1 consisted of 10 patients, who underwent 
secondary reconstruction after ablative surgery for malignant tumours. 
Four of them had pre-, or postoperative radiotherapy. In group 2, seven 
patients were included who were primarily reconstructed after resections 
for benign but aggressive odontogenic tumours. Group 3 consisted of 
three patients with severe atrophy and malunion. The defects ranged 
from 8 to 12 cm in group 1 and 2 and from 2 to 4 cm in group 3 and the 
follow-up from 1 to 8 years. The initial healing was uneventful in all but
3 patients. In 3 patients additional bone grafts had to be placed to allow
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for optimal implant placement. At the time of implant insertion some 
areas of granulation tissue were found, possibly due to the rather high 
dose of PRP used. Continuity in all cases was achieved and the patients 
considered the results as good in 10 cases and satisfying in 9 cases. One 
patient could not be approached for the last assessment. The grafting and 
fixation technique used proved to be rather reliable, but the concentration 
of PRP used was probably to high.
Conclusion and future perspectives
The results of this study reveal that there is no beneficial effect of PRP on 
the early and late bone healing in the present animal experiment. Although 
the goat model used is suitable for studying early bone healing, there are 
some drawbacks like the possibility of diffusion of PRP and /or its growth 
factors from the experimental to the control site. The in vitro experiments 
revealed no direct relation between the number of platelets and the levels 
of growth factors. PRP had a positive effect on the late proliferation of 
osteoblast-like cells. A beneficial effect on the differentiation of osteoblast­
like cells was, however, found in only one of the two in vitro experiments. 
Early angiogenesis was enhanced by a relatively low concentration of 
PRP. This may be an indication that the concentration of the PRP's used 
in many of the published studies is too high. Yet, the results of the clinical 
study described in this thesis suggest a beneficial effect of the addition of 
PRP, in spite of a relatively high concentration of the PRP's used.
In spite of all the confusing information on the working mechanism and 
effects of PRP products, further research in this field is indicated. For 
economical and biological reasons, PRP, or parts of PRP, may be valuable 
in wound and bone healing.
Standardization of the amount of platelets in the PRP used and exact 
determination of the growth factors in the different kinds of PRP is, 
of course, a prerequisite for follow-up studies. According to a recently 
published review article2 on the use of PRP in bone reconstructive therapy, 
activation of PRP by an optimal amount of calcium chloride and thrombin 
as described by Lacoste et al.3 should be a part of the protocol to obtain 
growth factors levels within a concentration range that is biological active. 
Collecting whole blood to prepare PRP, citrate-based anticoagulans rather 
than EDTA should be used, since EDTA can be detrimental to the platelet 
membrane2.
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When designing future studies on the use of PRP, also several other factors 
have to be taken into account.
One of the differences between the in vivo and in vitro studies is the fact 
that in the in vivo experiments, PRP is added to the experimental site only 
once. In the in vitro experiments, PRP is added several times according 
to a schedule. On the other hand in vitro experiments almost exclude 
environmental circumstances, which may have important influences on 
the working mechanism of PRP in vivo. For example, ex vivo activation 
of PRP may reveal an other outcome than a biological in vivo activation. 
Several studies have shown a dose dependent effect of PRP and it seems 
that the range between effective and ineffective is small. It is of course 
very important to determine this range, which probably varies between 
species and may be even between individuals of one species. This range 
may also be influenced by other (growth) factors, for example BMP's.
For instance, because of the individual variation of the number of platelets 
in each individual, it might be advisable to set up a study on human beings, 
using a five times concentration of platelets based on their individual 
baseline values. It would be interesting to learn whether the effects will 
be the same in each individual. It would also be possible that there is a 
variation of the content of the platelets in each individual and thus may 
the working mechanism differ from individual to individual. This may 
also be influenced by other factors such as growth factors present in the 
environment not derived from platelets. Further research using in vitro 
studies may be necessary to unravel the influence of the above mentioned 
factors.
A major drawback of most clinical studies, in which PRP is used to 
reconstruct large defects, is the lack of controls. When reconstructing 
large parts of the mandible, however, ethical considerations precluded 
such a study. For this reason an animal study, like one carried out by 
Fennis et al.1, might be a step forward to validate the findings as reported 
in this study.
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Voor reconstructies van het gezichtsskelet worden zowel gevascula- riseerde als ook niet gevasculariseerde bottransplantaten gebruikt. Gevasculariseerde transplantaten zijn de gouden standaard, 
omdat deze transplantaten qua overleving zeer betrouwbaar z^n, vooral 
als postoperatieve radiotherapie is geïndiceerd Een beperking van deze 
transplantaten is het relatief geringe botvolume en een gebrek aan 
mogelikheden om de oorspronkelike, drie dimensionale vorm, precies 
te herstellen. Dit geldt vooral voor de reconstructie van een betand 
deel van de mandibula. Het oogsten van bot veroorzaakt ook altid 
aanzienlike morbiditeit. "Tissue engineering" heeft wellicht de potentie 
om de esthetische en functionele resultaten van skeletale reconstructies te 
verbeteren, waarbi dan ook de morbiditeit van de donor zide kan worden 
voorkomen of tenminste wordt gereduceerd.
"Tissue engineering" vereist een matrix, (precursor) cellen en groeifactoren. 
Tot nu toe z in  "tissue engineering" technieken in de reconstructieve 
chirurgie van het gezichtsskelet nog niet geschikt om routinematig te 
worden toegepast.
Thrombocyten bevatten groeifactoren waarvan is aangetoond dat ze 
betrokken z in  b i de wondgenezing en in processen die aanleiding 
geven tot parenchymale cel proliferatie en weefsel regeneratie. Autologe 
of homologe thrombocytenconcentraten (platelet-rich plasma,PRP,) z^n 
goedkoop en gemakkelik te bereiden door de bloedbank of met behulp 
van "desktop" centrifugeapparaten (deze laatste alleen voor autoloog 
bloed). Om deze reden kan het gebruik van PRP in de reconstructieve 
chirurgie van het gezichtsskelet, veelbelovend zin. Ten tide dat deze 
studie werd begonnen, was er nauweliks bewiis voor een positief effect van 
het toevoegen van PRP aan autologe bottransplantaten of alloplastische 
botsubstituten. De vele dierexperimentele en enkele humane studies over 
het effect van PRP die in de afgelopen acht jaar z^n gepubliceerd, laten 
tegenstridige resultaten zien. Er is daarom nog steeds geen duidelikheid 
over het werkingsmechanisme en het eventuele positieve effect van PRP 
op de botgenezing.
De studies in dit proefschrift hebben de intentie om meer duidelikheid te 
verkrigen over het effect van PRP op de botgenezing.
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H oofdstuk  1 begint met een beschaving van de relevante inhoud 
(vesiculae/granulae) van thrombocyten. Er wordt nader ingegaan op 
de rol die verschillende belangrijke groeifactoren, a&omstig van de a- 
granulae van thrombocyten, in de wondgenezing hebben. De wiize waarop 
deze groeifactoren die na activatie van thrombocyten vrikomen, wordt 
beschreven. Er wordt een kort historisch overzicht over PRP gepresenteerd, 
waarna een samenvattend overzicht volgt van het gebruik van PRP in 
dierexperimentele en in vitro studies. Enkele mogelijke verklaringen voor 
de tegenstridige resultaten in deze studies worden besproken. Tenslotte 
wordt gerefereerd aan een recent systematisch overzichtsartikel naar het 
gebruik van PRP bij humane skeletale reconstructies, waarbij de nadruk 
wordt gelegd op diverse tekortkomingen i.e. substantiële heterogeniciteit 
en een gebrekkige studie opzet.
D o e ls te l l ing en :
1. Evaluatie van het vroege en late effect van PRP op de botgenezing.
H oofdstuk  2 handelt over een experiment met twintig geiten, waarbij per 
geit in het benige deel van het voorhoofd vier ronde, kritische defecten, 
werden gemaakt. Deze defecten werden gevuld met een gestandaardiseerde 
hoeveelheid gemalen autoloog bot, a&omstig van de crista iliaca anterior, 
waaraan in twee van de vier defecten een milliliter PRP was toegevoegd. 
Er traden geen postoperatieve complicaties op. Er waren vier subgroepen 
van elk vijf geiten. Het tijdstip waarop de geiten werden gedood verschilde 
per subgroep: 1, 2, 6 en 12 weken respectievelijk. De resultaten van het 
histologische en histomorphometrische onderzoek lieten geen verschil 
zien in de vroege en late botgenezing met respectievelijk zonder PRP.
2. Evaluatie van het vroege en late effect van PRP op de botgenezing van 
een mengsel van autoloog bot met een bot substituut.
H oofdstuk  3 beschrijft ook een experiment met twintig geiten, waarvoor 
hetzelfde model werd gebruikt als in hoofdstuk 2 beschreven. Om 
de hoeveelheid autoloog bot te reduceren, werd er een bot substituut 
toegevoegd. De gedachte was dat PRP de botgenezing van een mengsel 
van autoloog bot met een alloplastisch materiaal zou bevorderen. In 
dit experiment werd hiervoor een mengsel van gemalen autoloog bot 
met partikels gedeproteiniseerd runder bot (Bio-Oss®) gebruikt. De 
vier ronde kritische defecten in het voorhoofd van de geiten werden 
gevuld met bovengenoemd mengsel, waarbi aan twee van de vier
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mengsels een milliliter PRP was toegevoegd. Er traden wederom geen 
postoperatieve complicaties op. Ook deze groep werd in vier subgroepen 
van ieder 5 geiten verdeeld. De tijdstippen waarop de geiten van de 
respectievelijke subgroepen werden gedood, waren conform de studie in 
hoofdstuk 2: 1, 2, 6 en 12 weken. De resultaten van het histologische en 
histomorphometrische onderzoek lieten wederom geen verschil zien in 
de vroege en late botgenezing met en zonder PRP
3. Het kwantificeren van verschillende groeifactoren in PRP a&omstig 
van drie verschillende species en evaluatie van het effect van PRP op 
beenmergcellen van ratten.
In h oofdstuk  4  wordt een in vitro studie beschreven waarin de 
hoeveelheden van diverse groeifactoren van PRP's, a&omstig van drie 
verschillende species, met elkaar werden vergeleken. Tevens werd het 
effect van PRP op de proliferatie en differentiatie van beenmerg cellen 
van ratten geëvalueerd. De concentraties van TGF- |31, PDGF-AA, PDGF- 
AB, and PDGF-BB in ratten, geiten en menselijk PRP werden gemeten. Uit 
de metingen met immunoassays kwam naar voren dat over het algemeen 
humaan PRP per thrombocyt een hogere concentratie groeifactoren bevat 
dan ratten en geiten PRP. Geiten PRP bevatte weer meer groeifactoren 
per thrombocyt dan ratten PRP. Dit laatste gold niet voor PDGF-BB dat in 
een hogere concentratie in ratten PRP aanwezig was. In alle drie soorten 
PRP's was TGF-|31 de groeifactor met de hoogste concentratie.
De beenmergcellen van ratten werden gecultiveerd in wel of niet met PRP 
bedekte bakjes in een osteogeen medium gedurende een periode van 16 
dagen. De celproliferatie (m.b.v de hoeveelheid DNA) en celdifferentiatie 
(m.b.v alkalische fosfatase (ALP), hoeveelheid calcium, scanning 
elektronen microscopie en QPCR) werden gemeten. De resultaten lieten 
zien dat PRP initiële celgroei stimuleert, maar geen effect heeft op de ALP 
activiteit. De "real-time" PCR (poly chain reaction) resultaten lieten zien 
dat PRP osteocalcine liet toenemen op dag 1 en voor collageen type I gold 
dit op dag 8. De hoeveelheid calcium was significant verhoogd op dag 8, 
12 en 16.
De resultaten van deze in vitro studie z in  indicatief voor een verschil in 
de concentraties van groeifactoren per thrombocyt a&omstig van PRP's 
van verschillende species. Verder laat deze studie zien dat ratten PRP 
de initiële groei en differentiatie van beenmergcellen van ratten in vitro 
stimuleert.
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4. Het kwantificeren van de concentraties van verschillende groeifactoren 
a&omstig van twee verschillende humane PRP's.
5. Evaluatie van het effect van deze twee verschillende PRP's op 
osteoblastachtige cellen van ratten.
6. Het vaststellen van een optimale concentratie van PRP om de vroege 
angiogenese te stimuleren.
In hoofdstuk  5  worden de resultaten van een in vitro studie beschreven. 
Twee gestandaardiseerde PRP's, a&omstig van 10 humane donoren, 
werden nader geanalyseerd en hun effect op twee soorten cellen werd 
geëvalueerd. Per donor werden er twee verschillende PRP's, met 
significant verschillende thrombocytenconcentraties, gemaakt, . Een PRP 
met een thrombocytenconcentratie van 5 maal de gemiddelde waarde 
van de thrombocytenconcentratie in menselijk bloed en een PRP met 
een thrombocytenconcentratie van 5 maal de maximale waarde van de 
thrombocytenconcentratie in menselijk bloed.
Van beide PRP's werden de thrombocytenconcentraties gemeten. Na 
activatie van de PRP's werden door centrifuge supernatanten verkregen. 
Van alle supernatanten (PRP derivaten) werden de concentraties van de 
verschillende groeifactoren bepaald. Daarna werden deze supernatanten 
gebruikt in een celkweekexperiment met osteoblastachtige cellen van 
ratten en primaire humane endotheelcellen. De resultaten lieten zien dat 
er een significante toeneming was van de thrombocytenconcentratie in 
beide groepen PRP's ten opzichte van de thrombocytenconcentratie in 
het perifere bloed (volbloed) van de respectievelijke donoren. Ook tussen 
de beide groepen PRP's was de thrombocytenconcentratie significant 
verschillend. In beide groepen van PRP derivaten werd een significant 
hogere concentratie van de groeifactoren PDGF-AA, PDGF-AB en TGF-|3 
gemeten ten opzichte van de waarden in volbloed. Er werd geen significant 
verschil in de concentraties van deze groeifactoren tussen de beide 
groepen van PRP derivaten gevonden. De concentratie van VEGF was 
alleen significant verhoogd in de groep van PRP derivaten met de hoogste 
thrombocytenconcentraties. De celkweek experimenten lieten zien dat 
beide groepen van PRP derivaten de celproliferatie stimuleerden, maar 
dat er geen celdifferentiatie werd geïnduceerd. De tubuli vorming in de 
endotheelcelkweken nam ook significant toe door toevoeging van een laag 
volume percentage van beide groepen van PRP derivaten (2-8%). Op basis 
van deze resultaten werd geconcludeerd dat er geen directe relatie bestaat 
tussen het aantal thrombocyten en de hoeveelheid groeifactoren dat
164
samenvatting, toetsing van de doelstellingen, conclusie en toekom stperspectief
a&omstig is van deze thrombocyten. PRP derivaten blijken het vermogen 
te hebben om de angiogenese, dosis affiankelijk, te stimuleren. Toevoeging 
van PRP derivaten kan de celproliferatie significant stimuleren, maar 
deze PRP derivaten hebben niet de capaciteit om osteogene differentiatie 
te induceren.
7. Evaluatie van het effect van het gebruik van PRP bij grote reconstructies 
van de mandibula.
In hoofdstuk 6 wordt de klinische toepassing van PRP geëvalueerd. Bi 
twintig patiënten met mandibula defecten, werden reconstructies verricht. 
Er werd daarbij gebruik gemaakt van voorgevormde 2,3 mm titanium 
platen (Smart plates®) een autologe corticale botplaat, gemalen autoloog 
spongieus bot en PRP. De resultaten werden weergegeven in drie patiënten 
groepen. De eerste groep betrof 10 patiënten die in een eerder stadium 
ablatieve chirurgie hadden ondergaan in verband met een maligniteit. Bi 
hen werd een secundaire reconstructie van de mandibula verricht. Vier 
van deze patiënten ondergingen pre- of postoperatieve radiotherapie. De 
tweede groep bevatte 7 patiënten waarbij de mandibula primair werd 
gereconstrueerd nadat een benigne, maar agressieve odontogene tumor, 
werd verwijderd. De derde groep bestond uit drie patiënten met ernstige 
atrofie van de mandibula en een niet helende fractuur (pseudo-arthrose). 
De grootte van de defecten varieerden in groep een en twee van 8 tot 12 cm. 
en in groep drie van 2 tot 4 cm. De follow-up periode varieerde van 1 tot
8 jaar. Er was sprake van een goede wondgenezing, met uitzondering van 
drie patiënten, waarbi de initiële wondgenezing enigszins was gestoord. 
Bi drie patiënten was een additionele botaugmentatie nodig alvorens 
implantaten konden worden geplaatst. Tijdens exploratie ten behoeve 
van het plaatsen van de implantaten, werd er op sommige plekken wat 
granulatieweefsel aangetroffen. Dit was mogelijk ten gevolge van de 
relatief hoge concentratie thrombocyten in de gebruikte PRP's. In alle 
patiënten werd continuïteit van de mandibula gerealiseerd. De patiënten 
beoordeelden het resultaat in 10 gevallen als goed en in 9 gevallen als 
voldoende/bevredigend. Een patiënt kon niet worden benaderd voor een 
laatste beoordeling. De gebruikte techniek ten behoeve van reconstructie 
van de mandibula bleek betrouwbaar, maar de concentratie van de 
thrombocyten in de PRP's die werden toegevoegd was vermoedelijk te 
hoog.
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Conclusie en toekomstperspectief
De resultaten van deze studie laten zien dat PRP, in de gebruikte 
dierexperimenten, geenpositief effectheeftopdevroegeenlatebotgenezing. 
Het geitenmodel is weliswaar geschikt voor het bestuderen van de vroege 
botgenezing, maar er zijn wel enkele bezwaren, zoals de mogelijkheid van 
diffusie van PRP en/of groeifactoren van de onderzoekzijde naar de kant 
van de controle defecten. Uit de in vitro experimenten bleek geen directe 
relatie tussen het aantal thrombocyten en de hoeveelheid groeifactoren 
a&omstig uit deze thrombocyten. PRP had een positief effect op de late 
proliferatie van osteoblastachtige ratten cellen. Slechts in een van de twee 
in vitro experimenten werd ook een positief effect op de differentiatie 
van osteoblastachtige cellen aangetoond. De vroege angiogenese in 
celkweken werd positief beïnvloed door een relatief lage concentratie 
PRP. Dit fenomeen zou een indicatie kunnen z in  dat de concentraties van 
de verschillende PRP's, die in de vele gepubliceerde studies z in  gebruikt, 
te hoog waren.
De resultaten van de klinische studie van dit proefschrift suggeren toch 
een positief effect van de toevoeging van PRP, ondanks het feit dat de 
concentraties van de gebruikte PRP's relatief hoog waren.
Ondanks de verwarrende informatie over de effecten van PRP producten, 
is verder onderzoek hiervan geïndiceerd. Vooral omdat PRP, zowel om 
biologische als ook economische redenen, waardevol kan z in  voor de 
wond- en botgenezing.
In toekomstige studies op dit terrein, is het van belang om nauwkeuriger te 
bepalen welke doses maximaal effectief zijn. Dit betekent dat een verdere 
verfijning van de standaardisatie van de hoeveelheid thrombocyten in 
de veschillende PRP's, inclusief bepaling van de exacte hoeveelheden 
groeifactoren, noodzakelijk is. Andere factoren in de bereiding van PRP 
kunnen ook een rol spelen. In een recent overzichtsartikel van de Intini2 
over het gebruik van PRP in benige reconstructies, wordt aangegeven dat 
activatie van PRP door een optimale hoeveelheid van calciumchloride en 
thrombine, een onderdeel van het protocol zou moeten zijn. Dit werd ook 
reeds aangegeven door Lacoste et al.3. Hiermee zouden de hoeveelheden 
groeifactoren binnen biologisch actieve concentratiemarges komen te 
vallen. Verder lik t het aangewezen om bi het afnemen van volbloed ten 
behoeve van de bereiding van PRP geen EDTA, maar op citraat gebaseerde 
antistollings producten te gebruiken, omdat EDTA schadelik kan zin  
voor de thrombocyten membraan2.
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B i het ontwerpen van nieuwe studies over PRP, dient echter ook rekening 
te worden gehouden met nog andere factoren.
Een van de verschillen tussen in vitro en in vivo studies naar het effect 
van PRP is het feit dat in de in vivo studies PRP maar eenmalig aan de 
onderzoekszijde werd toegevoegd. In de in vitro experimenten werd PRP 
meestal volgens een bepaald schema op meer tijdstippen geappliceerd. 
Omgevingsfactoren, die een belangrijke invloed kunnen hebben in het 
werkingsmechanisme van PRP in vivo, z in  bi in vitro experimenten 
meestal afwezig. Ex vivo activatie van PRP zou bijvoorbeeld andere 
resultaten kunnen laten zien dan de biologische in vivo activatie. 
Enkele studies hebben een dosis affiankelijk effect van PRP laten zien 
en daarbi lik t het er tevens op dat het verschil tussen een werkzame 
en niet-werkzame dosis gering is. Het is uiteraard van groot belang om 
dit verschil en daarmee de concentratiebreedte van de optimale dosis 
te bepalen. Dit zal waarschijnlijk variëren per species en mogelijk zelfs 
tussen individuen van een species. Tevens zullen omgevingsfactoren, 
zoals de aanwezigheid van andere groeifactoren, bijvoorbeeld BMP's, van 
invloed kunnen zijn.
Vanwege de variatie van het aantal thrombocyten per individu, zou het in 
een toekomstige studie van belang kunnen z in  om een experiment op te 
zetten waarin een PRP wordt gebruikt met een thrombocytenconcentratie 
die 5 maal de individuele thrombocytenconcentratie van het individu is. 
Hierbi lik t het een interessante onderzoeksvraag of het effect van het 
zo bereide PRP per individu hetzelfde is. Het zou ook mogelijk kunnen 
z in  dat er een interindividuele variatie is van de samenstelling van de 
thrombocyten, waardoor het werkingsmechanisme van individu tot 
individu kan verschillen. Tevens zou het effect ook kunnen worden 
beïnvloed door (groei)factoren uit de omgeving die niet a&omstig zijn 
van thrombocyten. Gezien de complexiteit van deze problematiek, lijkt 
het dat men vooralsnog voornamelijk is aangewezen op in vitro studies 
teneinde de invloed van bovenstaande factoren te ontrafelen.
Een groot bezwaar van de meeste klinische studies, waarin PRP wordt 
gebruikt om een groot deel van de mandibula te reconstrueren, is het 
ontbreken van een controle groep. Om ethische redenen zal een dergelijke 
studie, met inclusie van een controle groep, uitgesloten zijn. Daarom zou 
een dierexperimentele studie, zoals uitgevoerd door Fennis et al.1, een 
goede methode kunnen zijn om uiteindelijk de resultaten van toekomstig 
in vitro onderzoek in vivo te valideren.
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